

Programa de Doctorat de Biomedicina
Facultat de Biologia
Bienni 2001-2003

Modulació de la sensibilitat a la gemcitabina mitjançant estratègies de teràpia gènica en càncer de pàncreas humà.

Memòria presentada per
Sandra Pérez Torras

Per optar al grau de
Doctor

Tesi doctoral sota la direcció de la **Dra. Adela Mazo Sánchez**
al Departament de Bioquímica i Biologia Molecular de la Universitat de Barcelona

La directora

L'autora

Adela Mazo

Sandra Pérez

Barcelona, Maig 2007

Bibliografia

A

- ACHIWA, H., OGURI, T., SATO, S., MAEDA, H., NIIMI, T., and UEDA, R. (2004). Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. *Cancer Sci* **95**, 753-757.
- AHMAD, S., CHEN, S., SUN, J., and LIN, X. (2003). Connexins 26 and 30 are co-assembled to form gap junctions in the cochlea of mice. *Biochem Biophys Res Commun* **307**, 362-368.
- ALBELDA, S.M., METTE, S.A., ELDER, D.E., STEWART, R., DAMJANOVICH, L., HERLYN, M., and BUCK, C.A. (1990). Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. *Cancer Res* **50**, 6757-6764.
- ALEMANY, R., BALAGUE, C., and CURIEL, D.T. (2000). Replicative adenoviruses for cancer therapy. *Nat Biotechnol* **18**, 723-727.
- ALEMANY, R., and CURIEL, D.T. (2001). CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors. *Gene Ther* **8**, 1347-1353.
- ALI, M., LEMOINE, N.R., and RING, C.J. (1994). The use of DNA viruses as vectors for gene therapy. *Gene Ther* **1**, 367-384.
- AMBRIOVIC, A., ADAM, M., MONTEIL, M., PAULIN, D., and ELOIT, M. (1997). Efficacy of replication-defective adenovirus-vectored vaccines: protection following intramuscular injection is linked to promoter efficiency in muscle representative cells. *Virology* **238**, 327-335.
- ANDERSON, C.M., XIONG, W., YOUNG, J.D., CASS, C.E., and PARKINSON, F.E. (1996). Demonstration of the existence of mRNAs encoding N1/cif and N2/cit sodium/nucleoside cotransporters in rat brain. *Brain Res Mol Brain Res* **42**, 358-361.
- ARAN, J.M., and PLAGEMANN, P.G. (1992). Nucleoside transport-deficient mutants of PK-15 pig kidney cell line. *Biochim Biophys Acta* **1110**, 51-58.
- ARNER, E.S., and ERIKSSON, S. (1995). Mammalian deoxyribonucleoside kinases. *Pharmacol Ther* **67**, 155-186.
- ASAMOTO, M., TAKAHASHI, S., IMAIDA, K., SHIRAI, T., and FUKUSHIMA, S. (1994). Increased gap junctional intercellular communication capacity and connexin 43 and 26 expression in rat bladder carcinogenesis. *Carcinogenesis* **15**, 2163-2166.

B

- BAAS, A.F., SMIT, L., and CLEVERS, H. (2004). LKB1 tumor suppressor protein: PArTaker in cell polarity. *Trends Cell Biol* **14**, 312-319.
- BALDWIN, S.A., BEAL, P.R., YAO, S.Y., KING, A.E., CASS, C.E., and YOUNG, J.D. (2004). The equilibrative nucleoside transporter family, SLC29. *Pflugers Arch* **447**, 735-743.
- BALDWIN, S.A., MACKAY, J.R., CASS, C.E., and YOUNG, J.D. (1999). Nucleoside transporters: molecular biology and implications for therapeutic development. *Mol Med Today* **5**, 216-224.
- BARAJAS, M., MAZZOLINI, G., GENOVE, G., BILBAO, R., NARVAIZA, I., SCHMITZ, V., SANGRO, B., MELERO, I., QIAN, C., and PRIETO, J. (2001). Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. *Hepatology* **33**, 52-61.
- BARDEESY, N., and DEPINHO, R.A. (2002). Pancreatic cancer biology and genetics. *Nat Rev Cancer* **2**, 897-909.
- BARNETT, B.G., CREWS, C.J., and DOUGLAS, J.T. (2002). Targeted adenoviral vectors. *Biochim Biophys Acta* **1575**, 1-14.
- BAXI, M.K., DEREGT, D., ROBERTSON, J., BABIUK, L.A., SCHLAPP, T., and TIKOO, S.K. (2000). Recombinant bovine adenovirus type 3 expressing bovine viral diarrhea virus glycoprotein E2 induces an immune response in cotton rats. *Virology* **278**, 234-243.
- BEACHY, P.A., KARHADKAR, S.S., and BERMAN, D.M. (2004). Mending and malignancy. *Nature* **431**, 402.
- BEAUSEJOUR, C.M., GAGNON, J., PRIMEAU, M., and MOMPALER, R.L. (2002). Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. *Biochem Biophys Res Commun* **293**, 1478-1484.
- BEERENS, A.M., AL HADITHY, A.F., ROTS, M.G., and HAISMA, H.J. (2003). Protein transduction domains and their utility in gene therapy. *Curr Gene Ther* **3**, 486-494.

- BELOUSOVA, N., KRENDELCHTCHIKOVA, V., CUIEL, D.T., and KRASNYKH, V. (2002). Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. *J Virol* **76**, 8621-8631.
- BENNETT, E.M., BENNINK, J.R., YEWEDELL, J.W., and BRODSKY, F.M. (1999). Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. *J Immunol* **162**, 5049-5052.
- BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURT-JONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. *Science* **275**, 1320-1323.
- BERGMAN, A.M., PINEDO, H.M., JONGSMA, A.P., BROUWER, M., RUIZ VAN HAPEREN, V.W., VEERMAN, G., LEYVA, A., ERIKSSON, S., and PETERS, G.J. (1999). Decreased resistance to gemcitabine (2',2'-difluorodeoxycytidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. *Biochem Pharmacol* **57**, 397-406.
- BERK, A.J. (1986). Adenovirus promoters and E1A transactivation. *Annu Rev Genet* **20**, 45-79.
- BERRINGTON DE GONZALEZ, A., SWEETLAND, S., and SPENCER, E. (2003). A meta-analysis of obesity and the risk of pancreatic cancer. *Br J Cancer* **89**, 519-523.
- BERTHOUD, V.M., MONTEGNA, E.A., ATAL, N., AITHAL, N.H., BRINK, P.R., and BEYER, E.C. (2001). Heteromeric connexons formed by the lens connexins, connexin43 and connexin56. *Eur J Cell Biol* **80**, 11-19.
- BEVANS, C.G., KORDEL, M., RHEE, S.K., and HARRIS, A.L. (1998). Isoform composition of connexin channels determines selectivity among second messengers and uncharged molecules. *J Biol Chem* **273**, 2808-2816.
- BI, W.L., PARYSEK, L.M., WARNICK, R., and STAMBROOK, P.J. (1993). *In vitro* evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. *Hum Gene Ther* **4**, 725-731.
- BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., NG, L., NYE, J.A., SAMPSON-JOHANNES, A., FATTAEY, A., and MCCORMICK, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. *Science* **274**, 373-376.
- BOADAS, J., MORA, J., URGELL, E., PUIG, P., ROCA, M., CUSO, X., CAPELLA, G., LLUIS, F., and FARRE, A. (2001). Clinical usefulness of K-ras gene mutation detection and cytology in pancreatic juice in the diagnosis and screening of pancreatic cancer. *Eur J Gastroenterol Hepatol* **13**, 1153-1159.
- BONNER-WEIR, S., and SHARMA, A. (2002). Pancreatic stem cells. *J Pathol* **197**, 519-526.
- BORST, P., and ELFERINK, R.O. (2002). Mammalian ABC transporters in health and disease. *Annu Rev Biochem* **71**, 537-592.
- BOSCHMAN, C.R., STRYKER, S., REDDY, J.K., and RAO, M.S. (1994). Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas. *Am J Pathol* **145**, 1291-1295.
- BOUFFARD, D.Y., and MOMPARTLER, R.L. (1995). Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside. *Leuk Res* **19**, 849-856.
- BRINK, P.R., CRONIN, K., BANACH, K., PETERSON, E., WESTPHALE, E.M., SEUL, K.H., RAMANAN, S.V., and BEYER, E.C. (1997). Evidence for heteromeric gap junction channels formed from rat connexin43 and human connexin37. *Am J Physiol* **273**, C1386-1396.
- BROOKS, J.R., and CULEBRAS, J.M. (1976). Cancer of the pancreas. Palliative operation, Whipple procedure, or total pancreatectomy? *Am J Surg* **131**, 516-520.
- BRUGGE, W.R., LAUWERS, G.Y., SAHANI, D., FERNANDEZ-DEL CASTILLO, C., and WARSHAW, A.L. (2004). Cystic neoplasms of the pancreas. *N Engl J Med* **351**, 1218-1226.
- BRUZZONE, R., WHITE, T.W., and GOODENOUGH, D.A. (1996). The cellular Internet: on-line with connexins. *Bioessays* **18**, 709-718.
- BURRIS, H., and STORNILOLO, A.M. (1997). Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. *Eur J Cancer* **33 Suppl 1**, S18-22.

C

- CALDAS, C., HAHN, S.A., HRUBAN, R.H., REDSTON, M.S., YEO, C.J., and KERN, S.E. (1994). Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. *Cancer Res* **54**, 3568-3573.
- CAMPBELL, S.L., KHOSRAVI-FAR, R., ROSSMAN, K.L., CLARK, G.J., and DER, C.J. (1998). Increasing complexity of Ras signaling. *Oncogene* **17**, 1395-1413.
- CAPELLA, G., CRONAUER-MITRA, S., PIENADO, M.A., and PERUCHO, M. (1991). Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. *Environ Health Perspect* **93**, 125-131.
- CARAS, I.W., and MARTIN, D.W., JR. (1988). Molecular cloning of the cDNA for a mutant mouse ribonucleotide reductase M1 that produces a dominant mutator phenotype in mammalian cells. *Mol Cell Biol* **8**, 2698-2704.
- CARRIO, M., MAZO, A., LOPEZ-IGLESIAS, C., ESTIVILL, X., and FILLAT, C. (2001). Retrovirus-mediated transfer of the herpes simplex virus thymidine kinase and connexin26 genes in pancreatic cells results in variable efficiency on the bystander killing: implications for gene therapy. *Int J Cancer* **94**, 81-88.
- CARRIO, M., ROMAGOSA, A., MERCADE, E., MAZO, A., NADAL, M., GOMEZ-FOIX, A.M., and FILLAT, C. (1999). Enhanced pancreatic tumor regression by a combination of adenovirus and retrovirus-mediated delivery of the herpes simplex virus thymidine kinase gene. *Gene Ther* **6**, 547-553.
- CASCALLO, M., CALBO, J., CAPELLA, G., FILLAT, C., PASTOR-ANGLADA, M., and MAZO, A. (2005). Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors. *Oncology* **68**, 179-189.
- CASCALLO, M., CALBO, J., GELPI, J.L., and MAZO, A. (2000). Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. *Cancer Gene Ther* **7**, 545-556.
- CASCANTE, A., HUCH, M., RODRIGUEZ, L.G., GONZALEZ, J.R., COSTANTINI, L., and FILLAT, C. (2005). Tat8-TK/GCV suicide gene therapy induces pancreatic tumor regression *in vivo*. *Hum Gene Ther* **16**, 1377-1388.
- CASHMAN, S.M., MORRIS, D.J., and KUMAR-SINGH, R. (2003). Evidence of protein transduction but not intercellular transport by proteins fused to HIV tat in retinal cell culture and *in vivo*. *Mol Ther* **8**, 130-142.
- CASTELLS, A., PUIG, P., MORA, J., BOADAS, J., BOIX, L., URGELL, E., SOLE, M., CAPELLA, G., LLUIS, F., FERNANDEZ-CRUZ, L., NAVARRO, S., and FARRE, A. (1999). K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. *J Clin Oncol* **17**, 578-584.
- CHAN, T.C. (1989). Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux. *Cancer Res* **49**, 2656-2660.
- CHEN, J.P., LIN, C., XU, C.P., ZHANG, X.Y., FU, M., DENG, Y.P., WEI, Y., and WU, M. (2001). Molecular therapy with recombinant antisense c-myc adenovirus for human gastric carcinoma cells *in vitro* and *in vivo*. *J Gastroenterol Hepatol* **16**, 22-28.
- CHENG, J.Q., RUGGERI, B., KLEIN, W.M., SONODA, G., ALTOMARE, D.A., WATSON, D.K., and TESTA, J.R. (1996). Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. *Proc Natl Acad Sci U S A* **93**, 3636-3641.
- CHIOCCA, E.A., ABBED, K.M., TATTER, S., LOUIS, D.N., HOCHBERG, F.H., BARKER, F., KRACHER, J., GROSSMAN, S.A., FISHER, J.D., CARSON, K., ROSENBLUM, M., MIKKELSEN, T., OLSON, J., MARKERT, J., ROSENFELD, S., NABORS, L.B., BREM, S., PHUPHANICH, S., FREEMAN, S., KAPLAN, R., and ZWIEBEL, J. (2004). A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. *Mol Ther* **10**, 958-966.
- CHOW, L., LAI, R., DABBAGH, L., BELCH, A., YOUNG, J.D., CASS, C.E., and MACKAY, J.R. (2005). Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry. *Mod Pathol* **18**, 558-564.

- CHRIST, M., LOUIS, B., STOECKEL, F., DIETERLE, A., GRAVE, L., DREYER, D., KINTZ, J., ALI HADJI, D., LUSKY, M., and MEHTALI, M. (2000). Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. *Hum Gene Ther* **11**, 415-427.
- CLAYMAN, G.L., EL-NAGGAR, A.K., LIPPMAN, S.M., HENDERSON, Y.C., FREDERICK, M., MERRITT, J.A., ZUMSTEIN, L.A., TIMMONS, T.M., LIU, T.J., GINSBERG, L., ROTH, J.A., HONG, W.K., BRUSO, P., and GOEPFERT, H. (1998). Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. *J Clin Oncol* **16**, 2221-2232.
- COCHAND-PRIOU, B., RAISON, D., MOLINIE, V., GUILLAUSSEAU, P.J., WASSEF, M., and BOUCHAUD, C. (1998). Altered gap and tight junctions in human thyroid oncocyctic tumors: a study of 8 cases by freeze-fracture. *Ultrastruct Pathol* **22**, 413-420.
- COE, I., ZHANG, Y., MCKENZIE, T., and NAYDENOVA, Z. (2002). PKC regulation of the human equilibrative nucleoside transporter, hENT1. *FEBS Lett* **517**, 201-205.
- CRAWFORD, C.R., NG, C.Y., NOEL, L.D., and BELT, J.A. (1990). Nucleoside transport in L1210 murine leukemia cells. Evidence for three transporters. *J Biol Chem* **265**, 9732-9736.
- CRAWFORD, C.R., PATEL, D.H., NAEVE, C., and BELT, J.A. (1998). Cloning of the human equilibrative, nitrobenzylmercaptapurine riboside (NBMPR)-insensitive nucleoside transporter ei by functional expression in a transport-deficient cell line. *J Biol Chem* **273**, 5288-5293.
- CSATARY, L.K., GOSZTONYI, G., SZEBERENYI, J., FABIAN, Z., LISZKA, V., BODEY, B., and CSATARY, C.M. (2004). MTH-68/H oncolytic viral treatment in human high-grade gliomas. *J Neurooncol* **67**, 83-93.
- CULVER, K.W., RAM, Z., WALLBRIDGE, S., ISHII, H., OLDFIELD, E.H., and BLAESE, R.M. (1992). *In vivo* gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. *Science* **256**, 1550-1552.

D

- DAS SARMA, J., MEYER, R.A., WANG, F., ABRAHAM, V., LO, C.W., and KOVAL, M. (2001). Multimeric connexin interactions prior to the trans-Golgi network. *J Cell Sci* **114**, 4013-4024.
- DAVIDSON, J., LIANDONG, M., IVERSON, P., LESOON, A., JIN, S., and HORWITZ, L. (2002). Human multi-drug resistance protein 5 (MRP5) confers resistance to gemcitabine. In (San Francisco).
- DE JONG, R.N., VAN DER VLIET, P.C., and BRENKMAN, A.B. (2003). Adenovirus DNA replication: protein priming, jumping back and the role of the DNA binding protein DBP. *Curr Top Microbiol Immunol* **272**, 187-211.
- DECHECCHI, M.C., MELOTTI, P., BONIZZATO, A., SANTACATTERINA, M., CHILOSI, M., and CABRINI, G. (2001). Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. *J Virol* **75**, 8772-8780.
- DELICADO, E.G., CASILLAS, T., SEN, R.P., and MIRAS-PORTUGAL, M.T. (1994). Evidence that adenine nucleotides modulate nucleoside-transporter function. Characterization of uridine transport in chromaffin cells and plasma membrane vesicles. *Eur J Biochem* **225**, 355-362.
- DENBY, L., WORK, L.M., GRAHAM, D., HSU, C., VON SEGGERN, D.J., NICKLIN, S.A., and BAKER, A.H. (2004). Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism *in vitro* and *in vivo*. *Hum Gene Ther* **15**, 1054-1064.
- DEWEESE, T.L., VAN DER POEL, H., LI, S., MIKHAK, B., DREW, R., GOEMANN, M., HAMPER, U., DEJONG, R., DETORIE, N., RODRIGUEZ, R., HAULK, T., DEMARZO, A.M., PIANTADOSI, S., YU, D.C., CHEN, Y., HENDERSON, D.R., CARDUCCI, M.A., NELSON, W.G., and SIMONS, J.W. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. *Cancer Res* **61**, 7464-7472.
- DIANXU, F., SHENGDAO, Z., TIANQUAN, H., YU, J., RUOQING, L., ZURONG, Y., and XUEZHI, W. (2002). A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. *Pancreas* **25**, 336-341.
- DIGIUSEPPE, J.A., HRUBAN, R.H., OFFERHAUS, G.J., CLEMENT, M.J., VAN DEN BERG, F.M., CAMERON, J.L., and VAN MANSFELD, A.D. (1994). Detection of K-ras mutations in mucinous pancreatic

- duct hyperplasia from a patient with a family history of pancreatic carcinoma. *Am J Pathol* **144**, 889-895.
- DILBER, M.S., ABEDI, M.R., CHRISTENSSON, B., BJORKSTRAND, B., KIDDER, G.M., NAUS, C.C., GAHRTON, G., and SMITH, C.I. (1997). Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase *in vivo*. *Cancer Res* **57**, 1523-1528.
- DIMAIO, J.M., CLARY, B.M., VIA, D.F., COVENEY, E., PAPPAS, T.N., and LYERLY, H.K. (1994). Directed enzyme pro-drug gene therapy for pancreatic cancer *in vivo*. *Surgery* **116**, 205-213.
- DMITRIEV, I., KRASNYKH, V., MILLER, C.R., WANG, M., KASHENTSEVA, E., MIKHEEVA, G., BELOUSOVA, N., and CUIEL, D.T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. *J Virol* **72**, 9706-9713.
- DMITRIEV, I.P., KASHENTSEVA, E.A., and CUIEL, D.T. (2002). Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. *J Virol* **76**, 6893-6899.
- DONEHOWER, L.A., HARVEY, M., SLAGLE, B.L., MCARTHUR, M.J., MONTGOMERY, C.A., JR., BUTEL, J.S., and BRADLEY, A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. *Nature* **356**, 215-221.
- DOUGLAS, J.T., MILLER, C.R., KIM, M., DMITRIEV, I., MIKHEEVA, G., KRASNYKH, V., and CUIEL, D.T. (1999). A system for the propagation of adenoviral vectors with genetically modified receptor specificities. *Nat Biotechnol* **17**, 470-475.
- DUFLOT-DANCER, A., PICCOLI, C., ROLLAND, A., YAMASAKI, H., and MESNIL, M. (1998). Long-term connexin-mediated bystander effect in highly tumorigenic human cells *in vivo* in herpes simplex virus thymidine kinase/ganciclovir gene therapy. *Gene Ther* **5**, 1372-1378.
- DUMONTET, C., BAUCHU, E.C., FABIANOWSKA, K., LEPOIVRE, M., WYCZECZOWSKA, D., BODIN, F., and ROLLAND, M.O. (1999a). Common resistance mechanisms to nucleoside analogues in variants of the human erythroleukemic line K562. *Adv Exp Med Biol* **457**, 571-577.
- DUMONTET, C., FABIANOWSKA-MAJEWSKA, K., MANTINCIC, D., CALLET BAUCHU, E., TIGAUD, I., GANDHI, V., LEPOIVRE, M., PETERS, G.J., ROLLAND, M.O., WYCZECZOWSKA, D., FANG, X., GAZZO, S., VOORN, D.A., VANIER-VIORNERY, A., and MACKAY, J. (1999b). Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. *Br J Haematol* **106**, 78-85.
- DURKIN, A.J., BLOOMSTON, P.M., ROSEMURGY, A.S., GIARELLI, N., COJITA, D., YEATMAN, T.J., and ZERVOS, E.E. (2003). Defining the role of the epidermal growth factor receptor in pancreatic cancer grown *in vitro*. *Am J Surg* **186**, 431-436.

E

- ELENES, S., MARTINEZ, A.D., DELMAR, M., BEYER, E.C., and MORENO, A.P. (2001). Heterotypic docking of Cx43 and Cx45 connexons blocks fast voltage gating of Cx43. *Biophys J* **81**, 1406-1418.
- ELLIOTT, G., and O'HARE, P. (1997). Intercellular trafficking and protein delivery by a herpesvirus structural protein. *Cell* **88**, 223-233.
- ELSALEH, H., POWELL, B., MCCAUL, K., GRIEU, F., GRANT, R., JOSEPH, D., and IACOPETTA, B. (2001). P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. *Clin Cancer Res* **7**, 1343-1349.
- ERIKSSON, S., KIERDASZUK, B., MUNCH-PETERSEN, B., OBERG, B., and JOHANSSON, N.G. (1991). Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. *Biochem Biophys Res Commun* **176**, 586-592.
- EVERETT, R.S., HODGES, B.L., DING, E.Y., XU, F., SERRA, D., and AMALFITANO, A. (2003). Liver toxicities typically induced by first-generation adenoviral vectors can be reduced by use of E1, E2b-deleted adenoviral vectors. *Hum Gene Ther* **14**, 1715-1726.
- EVERHART, J., and WRIGHT, D. (1995). Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. *Jama* **273**, 1605-1609.

EVERTS, M., and CUIEL, D.T. (2004). Transductional targeting of adenoviral cancer gene therapy. *Curr Gene Ther* **4**, 337-346.

F

- FALK, M.M., BUEHLER, L.K., KUMAR, N.M., and GILULA, N.B. (1997). Cell-free synthesis and assembly of connexins into functional gap junction membrane channels. *Embo J* **16**, 2703-2716.
- FARRE, X., GUILLEN-GOMEZ, E., SANCHEZ, L., HARDISSON, D., PLAZA, Y., LLOBERAS, J., CASADO, F.J., PALACIOS, J., and PASTOR-ANGLADA, M. (2004). Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. *Int J Cancer* **112**, 959-966.
- FAWELL, S., SEERY, J., DAIKH, Y., MOORE, C., CHEN, L.L., PEPINSKY, B., and BARSOU, J. (1994). Tat-mediated delivery of heterologous proteins into cells. *Proc Natl Acad Sci U S A* **91**, 664-668.
- FELIPE, A., VALDES, R., SANTO, B., LLOBERAS, J., CASADO, J., and PASTOR-ANGLADA, M. (1998). Na⁺-dependent nucleoside transport in liver: two different isoforms from the same gene family are expressed in liver cells. *Biochem J* **330** (Pt 2), 997-1001.
- FERRARI, A., PELLEGRINI, V., ARCANGELI, C., FITTIPALDI, A., GIACCA, M., and BELTRAM, F. (2003). Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. *Mol Ther* **8**, 284-294.
- FILIPOVIC, D.M., MENG, X., and REEVES, W.B. (1999). Inhibition of PARP prevents oxidant-induced necrosis but not apoptosis in LLC-PK1 cells. *Am J Physiol* **277**, F428-436.
- FLANAGAN, S.A., and MECKLING-GILL, K.A. (1997). Characterization of a novel Na⁺-dependent, guanosine-specific, nitrobenzylthioinosine-sensitive transporter in acute promyelocytic leukemia cells. *J Biol Chem* **272**, 18026-18032.
- FRANKE, T.F., TARTOF, K.D., and TSICHLIS, P.N. (1994). The SH2-like Akt homology (AH) domain of c-akt is present in multiple copies in the genome of vertebrate and invertebrate eucaryotes. Cloning and characterization of the *Drosophila melanogaster* c-akt homolog Dakt1. *Oncogene* **9**, 141-148.
- FREEMAN, S.M., ABOUD, C.N., WHARTENBY, K.A., PACKMAN, C.H., KOEPLIN, D.S., MOOLTEN, F.L., and ABRAHAM, G.N. (1993). The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. *Cancer Res* **53**, 5274-5283.
- FREYTAG, S.O., KHIL, M., STRICKER, H., PEABODY, J., MENON, M., DEPERALTA-VENTURINA, M., NAFZIGER, D., PEGG, J., PAIELLI, D., BROWN, S., BARTON, K., LU, M., AGUILAR-CORDOVA, E., and KIM, J.H. (2002). Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. *Cancer Res* **62**, 4968-4976.
- FREYTAG, S.O., STRICKER, H., PEGG, J., PAIELLI, D., PRADHAN, D.G., PEABODY, J., DEPERALTA-VENTURINA, M., XIA, X., BROWN, S., LU, M., and KIM, J.H. (2003). Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. *Cancer Res* **63**, 7497-7506.
- FRIESS, H., YAMANAKA, Y., BUCHLER, M., BERGER, H.G., KOBRIN, M.S., BALDWIN, R.L., and KORC, M. (1993). Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. *Cancer Res* **53**, 2704-2707.
- FRIESS, H., YAMANAKA, Y., BUCHLER, M., KOBRIN, M.S., TAHARA, E., and KORC, M. (1994). Cripto, a member of the epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis. *Int J Cancer* **56**, 668-674.
- FRIESS, H., YAMANAKA, Y., KOBRIN, M.S., DO, D.A., BUCHLER, M.W., and KORC, M. (1995). Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. *Clin Cancer Res* **1**, 1413-1420.
- FUCHS, C.S., COLDITZ, G.A., STAMPFER, M.J., GIOVANNUCCI, E.L., HUNTER, D.J., RIMM, E.B., WILLETT, W.C., and SPEIZER, F.E. (1996). A prospective study of cigarette smoking and the risk of pancreatic cancer. *Arch Intern Med* **156**, 2255-2260.

- FUEYO, J., GOMEZ-MANZANO, C., ALEMANY, R., LEE, P.S., MCDONNELL, T.J., MITLIANGA, P., SHI, Y.X., LEVIN, V.A., YUNG, W.K., and KYRITSIS, A.P. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect *in vivo*. *Oncogene* **19**, 2-12.
- FUXE, J., LIU, L., MALIN, S., PHILIPSON, L., COLLINS, V.P., and PETTERSSON, R.F. (2003). Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. *Int J Cancer* **103**, 723-729.

G

- GALANIS, E., OKUNO, S.H., NASCIMENTO, A.G., LEWIS, B.D., LEE, R.A., OLIVEIRA, A.M., SLOAN, J.A., ATHERTON, P., EDMONSON, J.H., ERLICHMAN, C., RANDLEV, B., WANG, Q., FREEMAN, S., and RUBIN, J. (2005). Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. *Gene Ther* **12**, 437-445.
- GALMARINI, C.M., CLARKE, M.L., JORDHEIM, L., SANTOS, C.L., CROS, E., MACKEY, J.R., and DUMONTET, C. (2004). Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. *BMC Pharmacol* **4**, 8.
- GALMARINI, C.M., MACKEY, J.R., and DUMONTET, C. (2002a). Nucleoside analogues and nucleobases in cancer treatment. *Lancet Oncol* **3**, 415-424.
- GALMARINI, C.M., THOMAS, X., CALVO, F., ROUSSELOT, P., EL JAFFARI, A., CROS, E., and DUMONTET, C. (2002b). Potential mechanisms of resistance to cytarabine in AML patients. *Leuk Res* **26**, 621-629.
- GALMARINI, C.M., THOMAS, X., CALVO, F., ROUSSELOT, P., RABILLOUD, M., EL JAFFARI, A., CROS, E., and DUMONTET, C. (2002c). *In vivo* mechanisms of resistance to cytarabine in acute myeloid leukaemia. *Br J Haematol* **117**, 860-868.
- GANDHI, V., MINEISHI, S., HUANG, P., CHAPMAN, A.J., YANG, Y., CHEN, F., NOWAK, B., CHUBB, S., HERTEL, L.W., and PLUNKETT, W. (1995). Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. *Cancer Res* **55**, 1517-1524.
- GANJAVI, H., GEE, M., NARENDRAN, A., FREEDMAN, M.H., and MALKIN, D. (2005). Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. *Cancer Gene Ther* **12**, 397-406.
- GANLY, I., KIM, Y.T., HANN, B., BALMAIN, A., and BROWN, R. (2001). Replication and cytolysis of an E1B-attenuated adenovirus in drug-resistant ovarian tumour cells is associated with reduced apoptosis. *Gene Ther* **8**, 369-375.
- GANLY, I., KIRN, D., ECKHARDT, G., RODRIGUEZ, G.I., SOUTAR, D.S., OTTO, R., ROBERTSON, A.G., PARK, O., GULLEY, M.L., HEISE, C., VON HOFF, D.D., and KAYE, S.B. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. *Clin Cancer Res* **6**, 798-806.
- GAPSTUR, S.M., GANN, P.H., LOWE, W., LIU, K., COLANGELO, L., and DYER, A. (2000). Abnormal glucose metabolism and pancreatic cancer mortality. *Jama* **283**, 2552-2558.
- GATI, W.P., PATERSON, A.R., LARRATT, L.M., TURNER, A.R., and BELCH, A.R. (1997). Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTA-fluorescein. *Blood* **90**, 346-353.
- GAVRIELI, Y., SHERMAN, Y., and BEN-SASSON, S.A. (1992). Identification of programmed cell death *in situ* via specific labeling of nuclear DNA fragmentation. *J Cell Biol* **119**, 493-501.
- GEMEL, J., VALIUNAS, V., BRINK, P.R., and BEYER, E.C. (2004). Connexin43 and connexin26 form gap junctions, but not heteromeric channels in co-expressing cells. *J Cell Sci* **117**, 2469-2480.
- GEOERGER, B., GRILL, J., OPOLON, P., MORIZET, J., AUBERT, G., LECLUSE, Y., VAN BEUSECHEM, V.W., GERRITSEN, W.R., KIRN, D.H., and VASSAL, G. (2003). Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. *Br J Cancer* **89**, 577-584.
- GEOERGER, B., VAN BEUSECHEM, V.W., OPOLON, P., MORIZET, J., LAUDANI, L., LECLUSE, Y., BARROIS, M., IDEMA, S., GRILL, J., GERRITSEN, W.R., and VASSAL, G. (2005). Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. *J Gene Med* **7**, 584-594.

- GEOERGER, B., VASSAL, G., OPOLON, P., DIRVEN, C.M., MORIZET, J., LAUDANI, L., GRILL, J., GIACCONE, G., VANDERTOP, W.P., GERRITSEN, W.R., and VAN BEUSECHEM, V.W. (2004). Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma. *Cancer Res* **64**, 5753-5759.
- GERDES, B., RAMASWAMY, A., KERSTING, M., ERNST, M., LANG, S., SCHUERMAN, M., WILD, A., and BARTSCH, D.K. (2001). p16(INK4a) alterations in chronic pancreatitis-indicator for high-risk lesions for pancreatic cancer. *Surgery* **129**, 490-497.
- GLADSON, C.L., and CHERESH, D.A. (1991). Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. *J Clin Invest* **88**, 1924-1932.
- GOAN, Y.G., ZHOU, B., HU, E., MI, S., and YEN, Y. (1999). Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. *Cancer Res* **59**, 4204-4207.
- GOGGINS, M., HRUBAN, R.H., and KERN, S.E. (2000). BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. *Am J Pathol* **156**, 1767-1771.
- GOGGINS, M., SCHUTTE, M., LU, J., MOSKALUK, C.A., WEINSTEIN, C.L., PETERSEN, G.M., YEO, C.J., JACKSON, C.E., LYNCH, H.T., HRUBAN, R.H., and KERN, S.E. (1996). Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. *Cancer Res* **56**, 5360-5364.
- GOLDBERG, G.S., LAMPE, P.D., SHEEDY, D., STEWART, C.C., NICHOLSON, B.J., and NAUS, C.C. (1998). Direct isolation and analysis of endogenous transjunctional ADP from Cx43 transfected C6 glioma cells. *Exp Cell Res* **239**, 82-92.
- GOURDEAU, H., CLARKE, M.L., OUELLET, F., MOWLES, D., SELNER, M., RICHARD, A., LEE, N., MACKEY, J.R., YOUNG, J.D., JOLIVET, J., LAFRENIERE, R.G., and CASS, C.E. (2001). Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines. *Cancer Res* **61**, 7217-7224.
- GRABER, H.U., FRIESS, H., KAUFMANN, B., WILLI, D., ZIMMERMANN, A., KORC, M., and BUCHLER, M.W. (1999). ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer. *Int J Cancer* **84**, 24-27.
- GREENBERG, N., SCHUMM, D.E., and WEBB, T.E. (1977). Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma. *Biochem J* **164**, 379-387.
- GRIFFITH, D.A., and JARVIS, S.M. (1996). Nucleoside and nucleobase transport systems of mammalian cells. *Biochim Biophys Acta* **1286**, 153-181.
- GRIFFITHS, M., BEAUMONT, N., YAO, S.Y., SUNDARAM, M., BOUMAH, C.E., DAVIES, A., KWONG, F.Y., COE, I., CASS, C.E., YOUNG, J.D., and BALDWIN, S.A. (1997a). Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. *Nat Med* **3**, 89-93.
- GRIFFITHS, M., YAO, S.Y., ABIDI, F., PHILLIPS, S.E., CASS, C.E., YOUNG, J.D., and BALDWIN, S.A. (1997b). Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. *Biochem J* **328 (Pt 3)**, 739-743.
- GUERRIER, A., FONLUPT, P., MORAND, I., RABILLOUD, R., AUDEBET, C., KRUTOVSKIKH, V., GROS, D., ROUSSET, B., and MUNARI-SILEM, Y. (1995). Gap junctions and cell polarity: connexin32 and connexin43 expressed in polarized thyroid epithelial cells assemble into separate gap junctions, which are located in distinct regions of the lateral plasma membrane domain. *J Cell Sci* **108 (Pt 7)**, 2609-2617.
- GUILLEN-GOMEZ, E., CALBET, M., CASADO, J., DE LECEA, L., SORIANO, E., PASTOR-ANGLADA, M., and BURGAYA, F. (2004). Distribution of CNT2 and ENT1 transcripts in rat brain: selective decrease of CNT2 mRNA in the cerebral cortex of sleep-deprived rats. *J Neurochem* **90**, 883-893.
- GUO, Y., KOTOVA, E., CHEN, Z.S., LEE, K., HOPPER-BORGE, E., BELINSKY, M.G., and KRUIH, G.D. (2003). MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. *J Biol Chem* **278**, 29509-29514.

GUTIERREZ, M.M., and GIACOMINI, K.M. (1993). Substrate selectivity, potential sensitivity and stoichiometry of Na(+)-nucleoside transport in brush border membrane vesicles from human kidney. *Biochim Biophys Acta* **1149**, 202-208.

H

- HA, H.C., and SNYDER, S.H. (1999). Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. *Proc Natl Acad Sci U S A* **96**, 13978-13982.
- HABIB, N., SALAMA, H., ABD EL LATIF ABU MEDIAN, A., ISAC ANIS, I., ABD AL AZIZ, R.A., SARRAF, C., MITRY, R., HAVLIK, R., SETH, P., HARTWIGSEN, J., BHUSHAN, R., NICHOLLS, J., and JENSEN, S. (2002). Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. *Cancer Gene Ther* **9**, 254-259.
- HAHN, S.A., SEYMOUR, A.B., HOQUE, A.T., SCHUTTE, M., DA COSTA, L.T., REDSTON, M.S., CALDAS, C., WEINSTEIN, C.L., FISCHER, A., YEO, C.J., and ET AL. (1995). Allelotype of pancreatic adenocarcinoma using xenograft enrichment. *Cancer Res* **55**, 4670-4675.
- HAMILTON, S.R., YAO, S.Y., INGRAM, J.C., HENDERSON, P.J., GALLAGHER, M., CASS, C., YOUNG, J.D., and BALDWIN, S.A. (1997). Anti-peptide antibodies as probes of the structure and subcellular distribution of the sodium-dependent nucleoside transporter rCNT1. In (Sheffield).
- HANAHAH, D., and WEINBERG, R.A. (2000). The hallmarks of cancer. *Cell* **100**, 57-70.
- HARADA, J.N., and BERK, A.J. (1999). p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. *J Virol* **73**, 5333-5344.
- HARBOUR, J.W., and DEAN, D.C. (2001). Corepressors and retinoblastoma protein function. *Curr Top Microbiol Immunol* **254**, 137-144.
- HARDING, J., and BURTNES, B. (2005). Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. *Drugs Today (Barc)* **41**, 107-127.
- HARRIS, A.L. (2001). Emerging issues of connexin channels: biophysics fills the gap. *Q Rev Biophys* **34**, 325-472.
- HARROW, S., PAPANASTASSIOU, V., HARLAND, J., MABBS, R., PETTY, R., FRASER, M., HADLEY, D., PATTERSON, J., BROWN, S.M., and RAMPLING, R. (2004). HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. *Gene Ther* **11**, 1648-1658.
- HE, D.S., JIANG, J.X., TAFFET, S.M., and BURT, J.M. (1999). Formation of heteromeric gap junction channels by connexins 40 and 43 in vascular smooth muscle cells. *Proc Natl Acad Sci U S A* **96**, 6495-6500.
- HEIDEMAN, D.A., STEENBERGEN, R.D., VAN DER TORRE, J., SCHEFFNER, M., ALEMANY, R., GERRITSEN, W.R., MEIJER, C.J., SNIJDERS, P.J., and VAN BEUSECHEM, V.W. (2005). Oncolytic adenovirus expressing a p53 variant resistant to degradation by HPV E6 protein exhibits potent and selective replication in cervical cancer. *Mol Ther* **12**, 1083-1090.
- HEINEMANN, V., HERTEL, L.W., GRINDEY, G.B., and PLUNKETT, W. (1988). Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. *Cancer Res* **48**, 4024-4031.
- HEINEMANN, V., SCHULZ, L., ISSELS, R.D., and PLUNKETT, W. (1995). Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. *Semin Oncol* **22**, 11-18.
- HEINMOLLER, E., DIETMAIER, W., ZIRNGIBL, H., HEINMOLLER, P., SCARINGE, W., JAUCH, K.W., HOFSTADTER, F., and RUSCHOFF, J. (2000). Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. *Am J Pathol* **157**, 83-92.
- HEMMI, S., GEERTSEN, R., MEZZACASA, A., PETER, I., and DUMMER, R. (1998). The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. *Hum Gene Ther* **9**, 2363-2373.
- HEMMINKI, A., KANERVA, A., LIU, B., WANG, M., ALVAREZ, R.D., SIEGAL, G.P., and CURIEL, D.T. (2003). Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression. *Cancer Res* **63**, 847-853.
- HENDERSON, R.A., MOSSMAN, S., NAIRN, N., and CHEEVER, M.A. (2005). Cancer vaccines and immunotherapies: emerging perspectives. *Vaccine* **23**, 2359-2362.

- HERMAN, J.R., ADLER, H.L., AGUILAR-CORDOVA, E., ROJAS-MARTINEZ, A., WOO, S., TIMME, T.L., WHEELER, T.M., THOMPSON, T.C., and SCARDINO, P.T. (1999). In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. *Hum Gene Ther* **10**, 1239-1249.
- HEZEL, A.F., KIMMELMAN, A.C., STANGER, B.Z., BARDEESY, N., and DEPINHO, R.A. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. *Genes Dev* **20**, 1218-1249.
- HILGERS, W., and KERN, S.E. (1999). Molecular genetic basis of pancreatic adenocarcinoma. *Genes Chromosomes Cancer* **26**, 1-12.
- HINGORANI, S.R., PETRICOIN, E.F., MAITRA, A., RAJAPAKSE, V., KING, C., JACOBETZ, M.A., ROSS, S., CONRADS, T.P., VEENSTRA, T.D., HITT, B.A., KAWAGUCHI, Y., JOHANN, D., LIOTTA, L.A., CRAWFORD, H.C., PUTT, M.E., JACKS, T., WRIGHT, C.V., HRUBAN, R.H., LOWY, A.M., and TUVESON, D.A. (2003). Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell* **4**, 437-450.
- HINGORANI, S.R., WANG, L., MULTANI, A.S., COMBS, C., DERAMAUDT, T.B., HRUBAN, R.H., RUSTGI, A.K., CHANG, S., and TUVESON, D.A. (2005). Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. *Cancer Cell* **7**, 469-483.
- HOOD, J.D. and CHERESH, D.A. (2002). Role of integrins in cell invasion and migration. *Nat Rev Cancer* Feb;2(2):91-100.
- HRUBAN, R.H., ADSAY, N.V., ALBORES-SAAVEDRA, J., COMPTON, C., GARRETT, E.S., GOODMAN, S.N., KERN, S.E., KLIMSTRA, D.S., KLOPPEL, G., LONGNECKER, D.S., LUTTGES, J., and OFFERHAUS, G.J. (2001). Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. *Am J Surg Pathol* **25**, 579-586.
- HRUBAN, R.H., GOGGINS, M., PARSONS, J., and KERN, S.E. (2000). Progression model for pancreatic cancer. *Clin Cancer Res* **6**, 2969-2972.
- HUA, Z., ZHANG, Y.C., HU, X.M., and JIA, Z.G. (2003). Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma. *World J Gastroenterol* **9**, 2764-2767.
- HUANG, Y., ANDERLE, P., BUSSEY, K.J., BARBACIORU, C., SHANKAVARAM, U., DAI, Z., REINHOLD, W.C., PAPP, A., WEINSTEIN, J.N., and SADEE, W. (2004). Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. *Cancer Res* **64**, 4294-4301.
- HUNSUCKER, S.A., SPYCHALA, J., and MITCHELL, B.S. (2001). Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance. *J Biol Chem* **276**, 10498-10504.
- HYDE, R.J., CASS, C.E., YOUNG, J.D., and BALDWIN, S.A. (2001). The ENT family of eukaryote nucleoside and nucleobase transporters: recent advances in the investigation of structure/function relationships and the identification of novel isoforms. *Mol Membr Biol* **18**, 53-63.

I

- IMMONEN, A., VAPALAHTI, M., TYYNELA, K., HURSKAINEN, H., SANDMAIR, A., VANNINEN, R., LANGFORD, G., MURRAY, N., and YLA-HERTTUALA, S. (2004). AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. *Mol Ther* **10**, 967-972.
- INABA, M., KOBAYASHI, T., TASHIRO, T., and SAKURAI, Y. (1988). Pharmacokinetic approach to rational therapeutic doses for human tumor-bearing nude mice. *Jpn J Cancer Res* **79**, 509-516.
- IRIE, A., MATSUMOTO, K., ANDEREGG, B., KURUMA, H., KASHANI-SABET, M., SCANLON, K.J., UCHIDA, T., and BABA, S. (2006). Growth inhibition efficacy of an adenovirus expressing dual therapeutic genes, wild-type p53, and anti-erbB2 ribozyme, against human bladder cancer cells. *Cancer Gene Ther* **13**, 298-305.

J

- JAFFEE, E.M., HRUBAN, R.H., CANTO, M., and KERN, S.E. (2002). Focus on pancreas cancer. *Cancer Cell* **2**, 25-28.

- JAMIESON, S., GOING, J.J., D'ARCY, R., and GEORGE, W.D. (1998). Expression of gap junction proteins connexin 26 and connexin 43 in normal human breast and in breast tumours. *J Pathol* **184**, 37-43.
- JARVIS, S.M., YOUNG, J.D., and ELLORY, J.C. (1980). Nucleoside transport in human erythrocytes. Apparent molecular weight of the nitrobenzylthioinosine-binding complex estimated by radiation-inactivation analysis. *Biochem J* **190**, 373-376.
- JASTER, R. (2004). Molecular regulation of pancreatic stellate cell function. *Mol Cancer* **3**, 26.
- JIANG, J.X., and GOODENOUGH, D.A. (1996). Heteromeric connexons in lens gap junction channels. *Proc Natl Acad Sci U S A* **93**, 1287-1291.
- JOHNSTON, J.B., DAENINCK, P., VERBURG, L., LEE, K., WILLIAMS, G., ISRAELS, L.G., MOWAT, M.R., and BEGLEITER, A. (1997). P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. *Leuk Lymphoma* **26**, 435-449.
- JOHNSTON, P.G., and KAYE, S. (2001). Capecitabine: a novel agent for the treatment of solid tumors. *Anticancer Drugs* **12**, 639-646.
- JOLIOT, A., PERNELLE, C., DEAGOSTINI-BAZIN, H., and PROCHIANTZ, A. (1991). Antennapedia homeobox peptide regulates neural morphogenesis. *Proc Natl Acad Sci U S A* **88**, 1864-1868.

K

- KANCZUGA-KODA, L., SULKOWSKA, M., KODA, M., RESZEC, J., FAMULSKI, W., BALTAZIAK, M., and SULKOWSKI, S. (2003). Expression of connexin 43 in breast cancer in comparison with mammary dysplasia and the normal mammary gland. *Folia Morphol (Warsz)* **62**, 439-442.
- KANCZUGA-KODA, L., SULKOWSKI, S., LENCZEWSKI, A., KODA, M., WINCEWICZ, A., BALTAZIAK, M., and SULKOWSKA, M. (2006). Increased expression of connexins 26 and 43 in lymph node metastases of breast cancer. *J Clin Pathol* **59**, 429-433.
- KERBEL, R.S. (2003). Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. *Cancer Biol Ther* **2**, S134-139.
- KIM, J., SMITH, T., IDAMAKANTI, N., MULGREW, K., KALOSS, M., KYLEFJORD, H., RYAN, P.C., KALEKO, M., and STEVENSON, S.C. (2002). Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization. *J Virol* **76**, 1892-1903.
- KIM, J.H., LEE, Y.S., KIM, H., HUANG, J.H., YOON, A.R., and YUN, C.O. (2006). Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy. *J Natl Cancer Inst* **98**, 1482-1493.
- KING, T.J., FUKUSHIMA, L.H., HIEBER, A.D., SHIMABUKURO, K.A., SAKR, W.A., and BERTRAM, J.S. (2000). Reduced levels of connexin43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression. *Carcinogenesis* **21**, 1097-1109.
- KLATZMANN, D., CHERIN, P., BENSIMON, G., BOYER, O., COUTELLIER, A., CHARLOTTE, F., BOCCACCIO, C., SALZMANN, J.L., and HERSON, S. (1998). A phase I/II dose-escalation study of herpes simplex virus type 1 thymidine kinase "suicide" gene therapy for metastatic melanoma. Study Group on Gene Therapy of Metastatic Melanoma. *Hum Gene Ther* **9**, 2585-2594.
- KOCH, P., GATFIELD, J., LOBER, C., HOBOM, U., LENZ-STOPLER, C., ROTH, J., and DOBBELSTEIN, M. (2001). Efficient replication of adenovirus despite the overexpression of active and nondegradable p53. *Cancer Res* **61**, 5941-5947.
- KONG, W., ENGEL, K., and WANG, J. (2004). Mammalian nucleoside transporters. *Curr Drug Metab* **5**, 63-84.
- KRASNYKH, V., DMITRIEV, I., MIKHEEVA, G., MILLER, C.R., BELOUSOVA, N., and CURIEL, D.T. (1998). Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. *J Virol* **72**, 1844-1852.
- KRASNYKH, V., DMITRIEV, I., NAVARRO, J.G., BELOUSOVA, N., KASHENTSEVA, E., XIANG, J., DOUGLAS, J.T., and CURIEL, D.T. (2000). Advanced generation adenoviral vectors possess augmented gene

- transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. *Cancer Res* **60**, 6784-6787.
- KRITZIK, M.R., JONES, E., CHEN, Z., KRAKOWSKI, M., KRAHL, T., GOOD, A., WRIGHT, C., FOX, H., and SARVETNICK, N. (1999). PDX-1 and Msx-2 expression in the regenerating and developing pancreas. *J Endocrinol* **163**, 523-530.
- KROEP, J.R., LOVES, W.J., VAN DER WILT, C.L., ALVAREZ, E., TALIANIDIS, I., BOVEN, E., BRAAKHUIS, B.J., VAN GROENINGEN, C.J., PINEDO, H.M., and PETERS, G.J. (2002). Pretreatment deoxycytidine kinase levels predict *in vivo* gemcitabine sensitivity. *Mol Cancer Ther* **1**, 371-376.
- KROEP, J.R., VAN MOORSEL, C.J., VEERMAN, G., VOORN, D.A., SCHULTZ, R.M., WORZALLA, J.F., TANZER, L.R., MERRIMAN, R.L., PINEDO, H.M., and PETERS, G.J. (1998). Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC). *Adv Exp Med Biol* **431**, 657-660.
- KRUTOVSKIKH, V., MAZZOLENI, G., MIRONOV, N., OMORI, Y., AGUELON, A.M., MESNIL, M., BERGER, F., PARTENSKY, C., and YAMASAKI, H. (1994). Altered homologous and heterologous gap-junctional intercellular communication in primary human liver tumors associated with aberrant protein localization but not gene mutation of connexin 32. *Int J Cancer* **56**, 87-94.
- KUMAR, N.M., and GILULA, N.B. (1992). Molecular biology and genetics of gap junction channels. *Semin Cell Biol* **3**, 3-16.
- KUMAR, N.M., and GILULA, N.B. (1996). The gap junction communication channel. *Cell* **84**, 381-388.
- KUNZ, B.A., KOHALMI, S.E., KUNKEL, T.A., MATHEWS, C.K., MCINTOSH, E.M., and REIDY, J.A. (1994). International Commission for Protection Against Environmental Mutagens and Carcinogens. Deoxyribonucleoside triphosphate levels: a critical factor in the maintenance of genetic stability. *Mutat Res* **318**, 1-64.

L

- LAEMMLI, U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680-685.
- LAMFERS, M.L., GRILL, J., DIRVEN, C.M., VAN BEUSECHEM, V.W., GEOERGER, B., VAN DEN BERG, J., ALEMANY, R., FUEYO, J., CURIEL, D.T., VASSAL, G., PINEDO, H.M., VANDERTOP, W.P., and GERRITSEN, W.R. (2002). Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. *Cancer Res* **62**, 5736-5742.
- LANG, F.F., BRUNER, J.M., FULLER, G.N., ALDAPE, K., PRADOS, M.D., CHANG, S., BERGER, M.S., MCDERMOTT, M.W., KUNWAR, S.M., JUNCK, L.R., CHANDLER, W., ZWIEBEL, J.A., KAPLAN, R.S., and YUNG, W.K. (2003). Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. *J Clin Oncol* **21**, 2508-2518.
- LANG, T.T., SELNER, M., YOUNG, J.D., and CASS, C.E. (2001). Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. *Mol Pharmacol* **60**, 1143-1152.
- LARRAYOZ, I.M., CASADO, F.J., PASTOR-ANGLADA, M., and LOSTAO, M.P. (2004). Electrophysiological characterization of the human Na(+)/nucleoside cotransporter 1 (hCNT1) and role of adenosine on hCNT1 function. *J Biol Chem* **279**, 8999-9007.
- LAWRENCE, A.G., and GHOSH, B.C. (1977). Total pancreatectomy for carcinoma of the pancreas. *Am J Surg* **133**, 244-246.
- LAWRENCE, T.S., CHANG, E.Y., HAHN, T.M., and SHEWACH, D.S. (1997). Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine). *Clin Cancer Res* **3**, 777-782.
- LEIFERT, J.A., HARKINS, S., and WHITTON, J.L. (2002). Full-length proteins attached to the HIV tat protein transduction domain are neither transduced between cells, nor exhibit enhanced immunogenicity. *Gene Ther* **9**, 1422-1428.
- LEIFERT, J.A., and WHITTON, J.L. (2003). "Translocatory proteins" and "protein transduction domains": a critical analysis of their biological effects and the underlying mechanisms. *Mol Ther* **8**, 13-20.

- LEMOINE, N.R., JAIN, S., HUGHES, C.M., STADDON, S.L., MAILLET, B., HALL, P.A., and KLOPPEL, G. (1992). Ki-ras oncogene activation in preinvasive pancreatic cancer. *Gastroenterology* **102**, 230-236.
- LEVY, L., and HILL, C.S. (2005). Smad4 dependency defines two classes of transforming growth factor {beta} (TGF-{beta}) target genes and distinguishes TGF-{beta}-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. *Mol Cell Biol* **25**, 8108-8125.
- LI, B., CHEN, F.Z., GE, X.H., CAI, M.Z., JIANG, J.S., LI, J.P., and LU, S.H. (2004). Pancreatoduodenectomy with vascular reconstruction in treating carcinoma of the pancreatic head. *Hepatobiliary Pancreat Dis Int* **3**, 612-615.
- LI, Y., PONG, R.C., BERGELSON, J.M., HALL, M.C., SAGALOWSKY, A.I., TSENG, C.P., WANG, Z., and HSIEH, J.T. (1999). Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. *Cancer Res* **59**, 325-330.
- LICHTY, B.D., STOJDL, D.F., TAYLOR, R.A., MILLER, L., FRENKEL, I., ATKINS, H., and BELL, J.C. (2004). Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. *Hum Gene Ther* **15**, 821-831.
- LIU, T.J., ZHANG, W.W., TAYLOR, D.L., ROTH, J.A., GOEPFERT, H., and CLAYMAN, G.L. (1994). Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. *Cancer Res* **54**, 3662-3667.
- LIZCANO, J.M., GORANSSON, O., TOTH, R., DEAK, M., MORRICE, N.A., BOUDEAU, J., HAWLEY, S.A., UDD, L., MAKELA, T.P., HARDIE, D.G., and ALESSI, D.R. (2004). LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. *Embo J* **23**, 833-843.
- LOHR, M., MAISONNEUVE, P., and LOWENFELS, A.B. (2000). K-Ras mutations and benign pancreatic disease. *Int J Pancreatol* **27**, 93-103.
- LOHR, M., SCHMIDT, C., RINGEL, J., KLUTH, M., MULLER, P., NIZZE, H., and JESNOWSKI, R. (2001). Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. *Cancer Res* **61**, 550-555.
- LOSTAO, M.P., MATA, J.F., LARRAYOZ, I.M., INZILLO, S.M., CASADO, F.J., and PASTOR-ANGLADA, M. (2000). Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in *Xenopus laevis* oocytes. *FEBS Lett* **481**, 137-140.
- LOTZE, M.T., and TRACEY, K.J. (2005). High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. *Nat Rev Immunol* **5**, 331-342.
- LU, X., GONG, S., MONKS, A., ZAHAREVITZ, D., and MOSCOW, J.A. (2002). Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity. *J Exp Ther Oncol* **2**, 200-212.
- LUNDBERG, M., WIKSTROM, S., and JOHANSSON, M. (2003). Cell surface adherence and endocytosis of protein transduction domains. *Mol Ther* **8**, 143-150.
- LYNCH, H.T., SMYRK, T., KERN, S.E., HRUBAN, R.H., LIGHTDALE, C.J., LEMON, S.J., LYNCH, J.F., FUSARO, L.R., FUSARO, R.M., and GHADIRIAN, P. (1996). Familial pancreatic cancer: a review. *Semin Oncol* **23**, 251-275.

M

- MACKEY, J.R., GALMARINI, C.M., GRAHAM, K.A., JOY, A.A., DELMER, A., DABBAGH, L., GLUBRECHT, D., JEWELL, L.D., LAI, R., LANG, T., HANSON, J., YOUNG, J.D., MERLE-BERAL, H., BINET, J.L., CASS, C.E., and DUMONTET, C. (2005). Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and -insensitive populations. *Blood* **105**, 767-774.
- MACKEY, J.R., JENNINGS, L.L., CLARKE, M.L., SANTOS, C.L., DABBAGH, L., VSIANSKA, M., KOSKI, S.L., COUPLAND, R.W., BALDWIN, S.A., YOUNG, J.D., and CASS, C.E. (2002). Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. *Clin Cancer Res* **8**, 110-116.
- MACKEY, J.R., MANI, R.S., SELNER, M., MOWLES, D., YOUNG, J.D., BELT, J.A., CRAWFORD, C.R., and CASS, C.E. (1998). Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. *Cancer Res* **58**, 4349-4357.

- MADRO, A., CELINSKI, K., and SLOMKA, M. (2004). The role of pancreatic stellate cells and cytokines in the development of chronic pancreatitis. *Med Sci Monit* **10**, RA166-170.
- MAITRA, A., ADSAY, N.V., ARGANI, P., IACOBUIZIO-DONAHUE, C., DE MARZO, A., CAMERON, J.L., YEO, C.J., and HRUBAN, R.H. (2003). Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. *Mod Pathol* **16**, 902-912.
- MAITRA, A., and HRUBAN, R.H. (2005). A new mouse model of pancreatic cancer: PTEN gets its Akt together. *Cancer Cell* **8**, 171-172.
- MAKINEN, K., LOIMAS, S., WAHLFORS, J., ALHAVA, E., and JANNE, J. (2000). Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer. *J Gene Med* **2**, 361-367.
- MAKOWER, D., ROZENBLIT, A., KAUFMAN, H., EDELMAN, M., LANE, M.E., ZWIEBEL, J., HAYNES, H., and WADLER, S. (2003). Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies. *Clin Cancer Res* **9**, 693-702.
- MALUMBRES, M., and BARBACID, M. (2003). RAS oncogenes: the first 30 years. *Nat Rev Cancer* **3**, 459-465.
- MANOME, Y., WEN, P.Y., DONG, Y., TANAKA, T., MITCHELL, B.S., KUFE, D.W., and FINE, H.A. (1996). Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside *in vitro* and *in vivo*. *Nat Med* **2**, 567-573.
- MARTINEZ, A.D., HAYRAPETYAN, V., MORENO, A.P., and BEYER, E.C. (2002). Connexin43 and connexin45 form heteromeric gap junction channels in which individual components determine permeability and regulation. *Circ Res* **90**, 1100-1107.
- MARZO, I., PEREZ-GALAN, P., GIRALDO, P., RUBIO-FELIX, D., ANEL, A., and NAVAL, J. (2001). Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. *Biochem J* **359**, 537-546.
- MASSAGUE, J., BLAIN, S.W., and LO, R.S. (2000). TGFbeta signaling in growth control, cancer, and heritable disorders. *Cell* **103**, 295-309.
- MATA, J.F., GARCIA-MANTEIGA, J.M., LOSTAO, M.P., FERNANDEZ-VELEDO, S., GUILLEN-GOMEZ, E., LARRAYOZ, I.M., LLOBERAS, J., CASADO, F.J., and PASTOR-ANGLADA, M. (2001). Role of the human concentrative nucleoside transporter (hCNT1) in the cytotoxic action of 5[Prime]-deoxy-5-fluorouridine, an active intermediate metabolite of capecitabine, a novel oral anticancer drug. *Mol Pharmacol* **59**, 1542-1548.
- MATHEWS, C.K. (2006). DNA precursor metabolism and genomic stability. *Faseb J* **20**, 1300-1314.
- MATROS, E., BAILEY, G., CLANCY, T., ZINNER, M., ASHLEY, S., WHANG, E. and REDSTON, M. (2006) Cytokeratin 20 Expression Identifies a Subtype of Pancreatic Adenocarcinoma with Decreased Overall Survival. *Cancer Feb 1;106(3):693-702*.
- MEDA, P., PEPPER, M.S., TRAUB, O., WILLECKE, K., GROS, D., BEYER, E., NICHOLSON, B., PAUL, D., and ORCI, L. (1993). Differential expression of gap junction connexins in endocrine and exocrine glands. *Endocrinology* **133**, 2371-2378.
- MEIER, O., BOUCKE, K., HAMMER, S.V., KELLER, S., STIDWILL, R.P., HEMMI, S., and GREBER, U.F. (2002). Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. *J Cell Biol* **158**, 1119-1131.
- MEIER, O., and GREBER, U.F. (2004). Adenovirus endocytosis. *J Gene Med* **6 Suppl 1**, S152-163.
- MESNIL, M. (2002). Connexins and cancer. *Biol Cell* **94**, 493-500.
- MESNIL, M., CRESPIAN, S., AVANZO, J.L., and ZAIDAN-DAGLI, M.L. (2005). Defective gap junctional intercellular communication in the carcinogenic process. *Biochim Biophys Acta* **1719**, 125-145.
- MESNIL, M., PICCOLI, C., TIRABY, G., WILLECKE, K., and YAMASAKI, H. (1996). Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. *Proc Natl Acad Sci U S A* **93**, 1831-1835.
- MESNIL, M., PICCOLI, C., and YAMASAKI, H. (1997). A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells. *Cancer Res* **57**, 2929-2932.

- MICHAUD, D.S., GIOVANNUCCI, E., WILLETT, W.C., COLDITZ, G.A., STAMPFER, M.J., and FUCHS, C.S. (2001). Physical activity, obesity, height, and the risk of pancreatic cancer. *Jama* **286**, 921-929.
- MILKS, L.C., KUMAR, N.M., HOUGHTEN, R., UNWIN, N., and GILULA, N.B. (1988). Topology of the 32-kd liver gap junction protein determined by site-directed antibody localizations. *Embo J* **7**, 2967-2975.
- MODESITT, S.C., RAMIREZ, P., ZU, Z., BODURKA-BEVERS, D., GERSHENSON, D., and WOLF, J.K. (2001). *In vitro* and *in vivo* adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. *Clin Cancer Res* **7**, 1765-1772.
- MOOLTEN, F.L., and WELLS, J.M. (1990). Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. *J Natl Cancer Inst* **82**, 297-300.
- MORABITO, F., FILANGERI, M., CALLEA, I., SCULLI, G., CALLEA, V., FRACCHIOLLA, N.S., NERI, A., and BRUGIATELLI, M. (1997). Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with *in vitro* sensitivity to chlorambucil and purine analogs. *Haematologica* **82**, 16-20.
- MUJOO, K., MANEVAL, D.C., ANDERSON, S.C., and GUTTERMAN, J.U. (1996). Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. *Oncogene* **12**, 1617-1623.
- MULVIHILL, S., WARREN, R., VENOOK, A., ADLER, A., RANDLEV, B., HEISE, C., and KIRN, D. (2001). Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. *Gene Ther* **8**, 308-315.
- MURPHY, K.M., BRUNE, K.A., GRIFFIN, C., SOLLENBERGER, J.E., PETERSEN, G.M., BANSAL, R., HRUBAN, R.H., and KERN, S.E. (2002). Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. *Cancer Res* **62**, 3789-3793.

N

- NAKANO, Y., TANNO, S., KOIZUMI, K., NISHIKAWA, T., NAKAMURA, K., MINOGUCHI, M., IZAWA, T., MIZUKAMI, Y., OKUMURA, T., and KOHGO, Y. (2007). Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. *Br J Cancer* **96**, 457-463.
- NEMEROW, G.R., and STEWART, P.L. (1999). Role of alpha(v) integrins in adenovirus cell entry and gene delivery. *Microbiol Mol Biol Rev* **63**, 725-734.
- NEMUNAITIS, J., CUNNINGHAM, C., BUCHANAN, A., BLACKBURN, A., EDELMAN, G., MAPLES, P., NETTO, G., TONG, A., RANDLEV, B., OLSON, S., and KIRN, D. (2001). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. *Gene Ther* **8**, 746-759.
- NIELSEN, L.L., DELL, J., MAXWELL, E., ARMSTRONG, L., MANEVAL, D., and CATINO, J.J. (1997). Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. *Cancer Gene Ther* **4**, 129-138.
- NIELSEN, S.E., MUNCH-PETERSEN, B., and MEJER, J. (1995). Increased ratio between deoxycytidine kinase and thymidine kinase 2 in CLL lymphocytes compared to normal lymphocytes. *Leuk Res* **19**, 443-447.
- NORMAN, K.L., HIRASAWA, K., YANG, A.D., SHIELDS, M.A., and LEE, P.W. (2004). Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. *Proc Natl Acad Sci U S A* **101**, 11099-11104.

O

- OGATA, N., UEDA, K., KAWAICHI, M., and HAYAISHI, O. (1981). Poly(ADP-ribose) synthetase, a main acceptor of poly(ADP-ribose) in isolated nuclei. *J Biol Chem* **256**, 4135-4137.
- OHASHI, M., KANAI, F., TANAKA, T., LAN, K.H., SHIRATORI, Y., KOMATSU, Y., KAWABE, T., YOSHIDA, H., HAMADA, H., and OMATA, M. (1998). *In vivo* adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing pancreatic cancer. *Jpn J Cancer Res* **89**, 457-462.

- OHNO, Y., SPRIGGS, D., MATSUKAGE, A., OHNO, T., and KUFE, D. (1988). Effects of 1-beta-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase beta. *Cancer Res* **48**, 1494-1498.
- OONUMA, M., SUNAMURA, M., MOTOI, F., FUKUYAMA, S., SHIMAMURA, H., YAMAUCHI, J., SHIBUYA, K., EGAWA, S., HAMADA, H., TAKEDA, K., and MATSUNO, S. (2002). Gene therapy for intraperitoneally disseminated pancreatic cancers by Escherichia coli uracil phosphoribosyltransferase (UPRT) gene mediated by restricted replication-competent adenoviral vectors. *Int J Cancer* **102**, 51-59.
- OSSIPOVA, O., BARDEESY, N., DEPINHO, R.A., and GREEN, J.B. (2003). LKB1 (XEEK1) regulates Wnt signalling in vertebrate development. *Nat Cell Biol* **5**, 889-894.
- OUBAN, A., MURACA, P., YEATMAN, T., and COPPOLA, D. (2003). Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. *Hum Pathol* **34**, 803-808.

P

- PAGLIARO, L.C., KEYHANI, A., LIU, B., PERROTTE, P., WILSON, D., and DINNEY, C.P. (2003). Adenoviral p53 gene transfer in human bladder cancer cell lines: cytotoxicity and synergy with cisplatin. *Urol Oncol* **21**, 456-462.
- PARIKH, N.S., CURRIER, M.A., MAHLER, Y.Y., ADAMS, L.C., DI PASQUALE, B., COLLINS, M.H., and CRIFE, T.P. (2005). Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models. *Pediatr Blood Cancer* **44**, 469-478.
- PARK, J.Y., ELSHAMI, A.A., AMIN, K., RIZK, N., KAISER, L.R., and ALBELDA, S.M. (1997). Retinoids augment the bystander effect *in vitro* and *in vivo* in herpes simplex virus thymidine kinase/ganciclovir-mediated gene therapy. *Gene Ther* **4**, 909-917.
- PARKER, L.P., WOLF, J.K., and PRICE, J.E. (2000). Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines. *Ann Clin Lab Sci* **30**, 395-405.
- PARKER, W.B., SHADDIX, S.C., ROSE, L.M., SHEWACH, D.S., HERTEL, L.W., SECRIST, J.A., 3RD, MONTGOMERY, J.A., and BENNETT, L.L., JR. (1999). Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-ribofuranosyl)adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-beta-D-ribofuranosyl)adenine in CEM cells. *Mol Pharmacol* **55**, 515-520.
- PASTOR-ANGLADA, M. (2006). *Nucleoside transport into cells: Role of nucleoside transporter SLC28 and SLC29 in cancer chemotherapy*. (Human Press).
- PASTOR-ANGLADA, M., FELIPE, A., and CASADO, F.J. (1998). Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. *Trends Pharmacol Sci* **19**, 424-430.
- PENNYCOOKE, M., CHAUDARY, N., SHURALYOVA, I., ZHANG, Y., and COE, I.R. (2001). Differential expression of human nucleoside transporters in normal and tumor tissue. *Biochem Biophys Res Commun* **280**, 951-959.
- PETERSEN, G.M., and HRUBAN, R.H. (2003). Familial pancreatic cancer: where are we in 2003? *J Natl Cancer Inst* **95**, 180-181.
- PISTERS, L.L., PETTAWAY, C.A., TRONCOSO, P., MCDONNELL, T.J., STEPHENS, L.C., WOOD, C.G., DO, K.A., BRISBAY, S.M., WANG, X., HOSSAN, E.A., EVANS, R.B., SOTO, C., JACOBSON, M.G., PARKER, K., MERRITT, J.A., STEINER, M.S., and LOGOTHETIS, C.J. (2004). Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. *Clin Cancer Res* **10**, 2587-2593.
- PLUNKETT, W., HUANG, P., SEARCY, C.E., and GANDHI, V. (1996). Gemcitabine: preclinical pharmacology and mechanisms of action. *Semin Oncol* **23**, 3-15.
- PLUNKETT, W., HUANG, P., XU, Y.Z., HEINEMANN, V., GRUNEWALD, R., and GANDHI, V. (1995). Gemcitabine: metabolism, mechanisms of action, and self-potential. *Semin Oncol* **22**, 3-10.
- POPKOV, M., JENDREYKO, N., MCGAVERN, D.B., RADER, C., and BARBAS, C.F., 3RD. (2005). Targeting tumor angiogenesis with adenovirus-delivered anti-Tie-2 intrabody. *Cancer Res* **65**, 972-981.

- PORTELLA, G., SCALA, S., VITAGLIANO, D., VECCHIO, G., and FUSCO, A. (2002). ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. *J Clin Endocrinol Metab* **87**, 2525-2531.
- PRATT, S., SHEPARD, R.L., KANDASAMY, R.A., JOHNSTON, P.A., PERRY, W., 3RD, and DANTZIG, A.H. (2005). The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. *Mol Cancer Ther* **4**, 855-863.

R

- RAKI, M., KANERVA, A., RISTIMAKI, A., DESMOND, R.A., CHEN, D.T., RANKI, T., SARKIOJA, M., KANGASNIEMI, L., and HEMMINKI, A. (2005). Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. *Gene Ther* **12**, 1198-1205.
- RAUCHWERGER, D.R., FIRBY, P.S., HEDLEY, D.W., and MOORE, M.J. (2000). Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. *Cancer Res* **60**, 6075-6079.
- REA, D., HAVENGA, M.J., VAN DEN ASSEM, M., SUTMULLER, R.P., LEMCKERT, A., HOEBEN, R.C., BOUT, A., MELIEF, C.J., and OFFRINGA, R. (2001). Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. *J Immunol* **166**, 5236-5244.
- REID, G., WIELINGA, P., ZELCER, N., DE HAAS, M., VAN DEEMTER, L., WIJNHOLDS, J., BALZARINI, J., and BORST, P. (2003). Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. *Mol Pharmacol* **63**, 1094-1103.
- REID, T., GALANIS, E., ABBRUZZESE, J., SZE, D., ANDREWS, J., ROMEL, L., HATFIELD, M., RUBIN, J., and KIRN, D. (2001). Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. *Gene Ther* **8**, 1618-1626.
- REIMAN, T., CLARKE, M.L., DABBAGH, L., VSIANSKA, M., COUPLAND, R.W., BELCH, A.R., BALDWIN, S.A., YOUNG, J.D., CASS, C.E., and MACKEY, J.R. (2002). Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed-Sternberg cells of Hodgkin's disease. *Leuk Lymphoma* **43**, 1435-1440.
- RESTA, R., YAMASHITA, Y., and THOMPSON, L.F. (1998). Ecto-enzyme and signaling functions of lymphocyte CD73. *Immunol Rev* **161**, 95-109.
- REYES, G., VILLANUEVA, A., GARCIA, C., SANCHO, F.J., PIULATS, J., LLUIS, F., and CAPELLA, G. (1996). Orthotopic xenografts of human pancreatic carcinomas acquire genetic aberrations during dissemination in nude mice. *Cancer Res* **56**, 5713-5719.
- RICHARD, J.P., MELIKOV, K., VIVES, E., RAMOS, C., VERBEURE, B., GAIT, M.J., CHERNOMORDIK, L.V., and LEBLEU, B. (2003). Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. *J Biol Chem* **278**, 585-590.
- RITZEL, M.W., NG, A.M., YAO, S.Y., GRAHAM, K., LOEWEN, S.K., SMITH, K.M., RITZEL, R.G., MOWLES, D.A., CARPENTER, P., CHEN, X.Z., KARPINSKI, E., HYDE, R.J., BALDWIN, S.A., CASS, C.E., and YOUNG, J.D. (2001). Molecular identification and characterization of novel human and mouse concentrative Na⁺-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). *J Biol Chem* **276**, 2914-2927.
- ROBE, P.A., PRINCEN, F., MARTIN, D., MALGRANGE, B., STEVENAERT, A., MOONEN, G., GIELEN, J., MERVILLE, M., and BOURS, V. (2000). Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system: effects of dibutyryl adenosine 3',5'-cyclic monophosphate, alpha-glycyrrhetic acid, and cytosine arabinoside. *Biochem Pharmacol* **60**, 241-249.
- ROBSON, T., and HIRST, D.G. (2003). Transcriptional Targeting in Cancer Gene Therapy. *J Biomed Biotechnol* **2003**, 110-137.
- ROCHA, S., CAMPBELL, K.J., and PERKINS, N.D. (2003). p53- and Mdm2-independent repression of NF-kappa B transactivation by the ARF tumor suppressor. *Mol Cell* **12**, 15-25.

- ROELVINK, P.W., MI LEE, G., EINFELD, D.A., KOVESDI, I., and WICKHAM, T.J. (1999). Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. *Science* **286**, 1568-1571.
- ROSENFELD, M.E., VICKERS, S.M., RABEN, D., WANG, M., SAMPSON, L., FENG, M., JAFFEE, E., and CURIEL, D.T. (1997). Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene. *Ann Surg* **225**, 609-618; discussion 618-620.
- Royds JA, Hibma M, Dix BR, Hananeia L, Russell IA, Wiles A, Wynford-Thomas D and Braithwaite AW (2006). p53 promotes adenoviral replication and increases late viral gene expression. *Oncogene* **9**;25(10):1509-20.
- ROWE, W.P., HUEBNER, R.J., GILMORE, L.K., PARROTT, R.H., and WARD, T.G. (1953). Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. *Proc Soc Exp Biol Med* **84**, 570-573.
- RUBIO-VIQUEIRA, B., JIMENO, A., CUSATIS, G., ZHANG, X., IACOBUZIO-DONAHUE, C., KARIKARI, C., SHI, C., DANENBERG, K., DANENBERG, P.V., KURAMOCHI, H., TANAKA, K., SINGH, S., SALIMI-MOOSAVI, H., BOURAOUD, N., AMADOR, M.L., ALTIOK, S., KULESZA, P., YEO, C., MESSERSMITH, W., ESHLEMAN, J., HRUBAN, R.H., MAITRA, A., and HIDALGO, M. (2006). An *in vivo* platform for translational drug development in pancreatic cancer. *Clin Cancer Res* **12**, 4652-4661.
- RUDOLPH, F.B. (1994). The biochemistry and physiology of nucleotides. *J Nutr* **124**, 124S-127S.
- RUIZ VAN HAPEREN, V.W., VEERMAN, G., ERIKSSON, S., BOVEN, E., STEGMANN, A.P., HERMSEN, M., VERMORKEN, J.B., PINEDO, H.M., and PETERS, G.J. (1994). Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. *Cancer Res* **54**, 4138-4143.
- RUIZ VAN HAPEREN, V.W., VEERMAN, G., ERIKSSON, S., STEGMANN, A.P., and PETERS, G.J. (1995). Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780. *Semin Oncol* **22**, 35-41.
- RUIZ VAN HAPEREN, V.W., VEERMAN, G., VERMORKEN, J.B., and PETERS, G.J. (1993). 2',2'-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. *Biochem Pharmacol* **46**, 762-766.
- RUOSLAHTI, E. (2002). Specialization of tumour vasculature. *Nat Rev Cancer* **2**, 83-90.
- ## S
- SABINI, E., ORT, S., MONNERJAHN, C., KONRAD, M., and LAVIE, A. (2003). Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. *Nat Struct Biol* **10**, 513-519.
- SACHS, M.D., RAMAMURTHY, M., POEL, H., WICKHAM, T.J., LAMFERS, M., GERRITSEN, W., CHOWDHURY, W., LI, Y., SCHOENBERG, M.P., and RODRIGUEZ, R. (2004). Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. *Cancer Gene Ther* **11**, 477-486.
- SAFRAN, H., STEINHOFF, M., MANGRAY, S., RATHORE, R., KING, T.C., CHAI, L., BERZEIN, K., MOORE, T., IANNITTI, D., REISS, P., PASQUARIELLO, T., AKERMAN, P., QUIRK, D., MASS, R., GOLDSTEIN, L., and TANTRAVAHU, U. (2001). Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. *Am J Clin Oncol* **24**, 496-499.
- SAITO, T., NISHIMURA, M., KUDO, R., and YAMASAKI, H. (2001). Suppressed gap junctional intercellular communication in carcinogenesis of endometrium. *Int J Cancer* **93**, 317-323.
- SAKAMOTO, H., OYAMADA, M., ENOMOTO, K., and MORI, M. (1992). Differential changes in expression of gap junction proteins connexin 26 and 32 during hepatocarcinogenesis in rats. *Jpn J Cancer Res* **83**, 1210-1215.
- SANDMAIR, A.M., LOIMAS, S., PURANEN, P., IMMONEN, A., KOSSILA, M., PURANEN, M., HURSKAINEN, H., TYYNELA, K., TURUNEN, M., VANNINEN, R., LEHTOLAINEN, P., PALJARVI, L., JOHANSSON, R., VAPALAHTI, M., and YLA-HERTTUALA, S. (2000). Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. *Hum Gene Ther* **11**, 2197-2205.
- SANGER, F., NICKLEN, S., and COULSON, A.R. (1977). DNA sequencing with chain-terminating inhibitors. *Proc Natl Acad Sci U S A* **74**, 5463-5467.

- SARKAR, M., HAN, T., DAMARAJU, V., CARPENTER, P., CASS, C.E., and AGARWAL, R.P. (2005). Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. *Biochem Pharmacol* **70**, 426-432.
- SASVARI-SZEKELY, M., CSAPO, Z., SPASOKOUKOTSKAJA, T., ERIKSSON, S., and STAUB, M. (1998). Activation of deoxycytidine kinase during inhibition of DNA synthesis in human lymphocytes. *Adv Exp Med Biol* **431**, 519-523.
- SAUTHOFF, H., PIPIYA, T., HEITNER, S., CHEN, S., NORMAN, R.G., ROM, W.N., and HAY, J.G. (2002). Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. *Hum Gene Ther* **13**, 1859-1871.
- SCHENK, M., SCHWARTZ, A.G., O'NEAL, E., KINNARD, M., GREENSON, J.K., FRYZEK, J.P., YING, G.S., and GARABRANT, D.H. (2001). Familial risk of pancreatic cancer. *J Natl Cancer Inst* **93**, 640-644.
- SCHIEDNER, G., BLOCH, W., HERTEL, S., JOHNSTON, M., MOLOJAVYI, A., DRIES, V., VARGA, G., VAN ROOIJEN, N., and KOCHANNEK, S. (2003). A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. *Hum Gene Ther* **14**, 1631-1641.
- SCHNEIDER, B., TESCHNER, M., SUDERMANN, T., PIKULA, B., and LAUTERMANN, J. (2002). Expression of gap junction proteins (connexin 26, 30, 32, 43) in normal mucosa, hyperkeratosis and carcinoma of the human larynx. *ORL J Otorhinolaryngol Relat Spec* **64**, 324-329.
- SCHUETZ, J.D., CONNELLY, M.C., SUN, D., PAIBIR, S.G., FLYNN, P.M., SRINIVAS, R.V., KUMAR, A., and FRIDLAND, A. (1999). MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. *Nat Med* **5**, 1048-1051.
- SCOGGINS, C.R., MESZOELY, I.M., WADA, M., MEANS, A.L., YANG, L., and LEACH, S.D. (2000). p53-dependent acinar cell apoptosis triggers epithelial proliferation in duct-ligated murine pancreas. *Am J Physiol Gastrointest Liver Physiol* **279**, G827-836.
- SEDMAK, J.J., and GROSSBERG, S.E. (1977). A rapid, sensitive, and versatile assay for protein using Coomassie brilliant blue G250. *Anal Biochem* **79**, 544-552.
- SEN, R.P., SOBREVIA, L., DELICADO, E.G., YUDILEVICH, D., and MIRAS-PORTUGAL, M.T. (1996). Bovine adrenal endothelial cells express nucleoside transporters nonregulated by protein kinases A and C. *Am J Physiol* **271**, C504-510.
- SERRANO, M., HANNON, G.J., and BEACH, D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. *Nature* **366**, 704-707.
- SERRANO, M., LEE, H., CHIN, L., CORDON-CARDO, C., BEACH, D., and DEPINHO, R.A. (1996). Role of the INK4a locus in tumor suppression and cell mortality. *Cell* **85**, 27-37.
- SHERLEY, J.L., and KELLY, T.J. (1988). Regulation of human thymidine kinase during the cell cycle. *J Biol Chem* **263**, 8350-8358.
- SHIEH, S.Y., IKEDA, M., TAYA, Y., and PRIVES, C. (1997). DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. *Cell* **91**, 325-334.
- SHILLITOE, E.J., and PELLEZZI, C. (2005). Factors that limit the effectiveness of herpes simplex virus type 1 for treatment of oral cancer in mice. *Clin Cancer Res* **11**, 3109-3116.
- SJOBERG, A.H., WANG, L., and ERIKSSON, S. (1998). Substrate specificity of human recombinant mitochondrial deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. *Mol Pharmacol* **53**, 270-273.
- SMID, K., VAN MOORSEL, C.J., NOORDHUIS, P., VOORN, D.A., and PETERS, G.J. (2001). Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay. *Int J Oncol* **19**, 157-162.
- SMITH, K.M., NG, A.M., YAO, S.Y., LABEDZ, K.A., KNAUS, E.E., WIEBE, L.I., CASS, C.E., BALDWIN, S.A., CHEN, X.Z., KARPINSKI, E., and YOUNG, J.D. (2004). Electrophysiological characterization of a recombinant human Na⁺-coupled nucleoside transporter (hCNT1) produced in *Xenopus* oocytes. *J Physiol* **558**, 807-823.
- SMITH, T., IDAMAKANTI, N., KYLEFJORD, H., ROLLENCE, M., KING, L., KALOSS, M., KALEKO, M., and STEVENSON, S.C. (2002). *In vivo* hepatic adenoviral gene delivery occurs independently of the coxsackievirus-adenovirus receptor. *Mol Ther* **5**, 770-779.

- SOBRERO, A.F., MOIR, R.D., BERTINO, J.R., and HANDSCHUMACHER, R.E. (1985). Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line. *Cancer Res* **45**, 3155-3160.
- SOLER, C., FELIPE, A., CASADO, F.J., CELADA, A., and PASTOR-ANGLADA, M. (2000). Nitric oxide regulates nucleoside transport in activated B lymphocytes. *J Leukoc Biol* **67**, 345-349.
- SOLER, C., FELIPE, A., GARCIA-MANTEIGA, J., SERRA, M., GUILLEN-GOMEZ, E., CASADO, F.J., MACLEOD, C., MODOLELL, M., PASTOR-ANGLADA, M., and CELADA, A. (2003). Interferon-gamma regulates nucleoside transport systems in macrophages through signal transduction and activator of transduction factor 1 (STAT1)-dependent and -independent signalling pathways. *Biochem J* **375**, 777-783.
- SOLER, C., FELIPE, A., MATA, J.F., CASADO, F.J., CELADA, A., and PASTOR-ANGLADA, M. (1998). Regulation of nucleoside transport by lipopolysaccharide, phorbol esters, and tumor necrosis factor-alpha in human B-lymphocytes. *J Biol Chem* **273**, 26939-26945.
- SPASOKOUKOTSKAJA, T., SASVARI-SZEKELY, M., HULLAN, L., ALBERTIONI, F., ERIKSSON, S., and STAUB, M. (1998). Activation of deoxycytidine kinase by various nucleoside analogues. *Adv Exp Med Biol* **431**, 641-645.
- SPITZ, F.R., NGUYEN, D., SKIBBER, J.M., CUSACK, J., ROTH, J.A., and CRISTIANO, R.J. (1996). *In vivo* adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. *Anticancer Res* **16**, 3415-3422.
- SPRATLIN, J., SANGHA, R., GLUBRECHT, D., DABBAGH, L., YOUNG, J.D., DUMONTET, C., CASS, C., LAI, R., and MACKAY, J.R. (2004). The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. *Clin Cancer Res* **10**, 6956-6961.
- STAM, R.W., DEN BOER, M.L., MEIJERINK, J.P., EBUS, M.E., PETERS, G.J., NOORDHUIS, P., JANKA-SCHAUB, G.E., ARMSTRONG, S.A., KORSMEYER, S.J., and PIETERS, R. (2003). Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. *Blood* **101**, 1270-1276.
- STERMAN, D.H., TREAT, J., LITZKY, L.A., AMIN, K.M., COONROD, L., MOLNAR-KIMBER, K., RECIO, A., KNOX, L., WILSON, J.M., ALBELDA, S.M., and KAISER, L.R. (1998). Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. *Hum Gene Ther* **9**, 1083-1092.
- STEWART, P.L., CHIU, C.Y., HUANG, S., MUIR, T., ZHAO, Y., CHAIT, B., MATHIAS, P., and NEMEROW, G.R. (1997). Cryo-EM visualization of an exposed RGD epitope on adenovirus that escapes antibody neutralization. *Embo J* **16**, 1189-1198.
- STOECKLEIN, N.H., LUEBKE, A.M., ERBERSDOBLER, A., KNOEFEL, W.T., SCHRAUT, W., VERDE, P.E., STERN, F., SCHEUNEMANN, P., PEIPER, M., EISENBERGER, C.F., IZBICKI, J.R., KLEIN, C.A., and HOSCH, S.B. (2004). Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma. *J Clin Oncol* **22**, 4737-4745.
- STOLZENBERG-SOLOMON, R.Z., GRAUBARD, B.I., CHARI, S., LIMBURG, P., TAYLOR, P.R., VIRTAMO, J., and ALBANES, D. (2005). Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. *Jama* **294**, 2872-2878.
- SUGIMOTO, M., KUO, M.L., ROUSSEL, M.F., and SHERR, C.J. (2003). Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing. *Mol Cell* **11**, 415-424.
- SUNDARAM, M., YAO, S.Y., NG, A.M., GRIFFITHS, M., CASS, C.E., BALDWIN, S.A., and YOUNG, J.D. (1998). Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs. *J Biol Chem* **273**, 21519-21525.
- SUNDARARAJAN, R., CUCONATI, A., NELSON, D., and WHITE, E. (2001). Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19K. *J Biol Chem* **276**, 45120-45127.
- SUZUKI, A., DE LA POMPA, J.L., HAKEM, R., ELIA, A., YOSHIDA, R., MO, R., NISHINA, H., CHUANG, T., WAKEHAM, A., ITIE, A., KOO, W., BILLIA, P., HO, A., FUKUMOTO, M., HUI, C.C., and MAK, T.W.

- (1997). Brca2 is required for embryonic cellular proliferation in the mouse. *Genes Dev* **11**, 1242-1252.
- SUZUKI, K., FUEYO, J., KRASNYKH, V., REYNOLDS, P.N., CUIEL, D.T., and ALEMANY, R. (2001). A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. *Clin Cancer Res* **7**, 120-126.
- SWISHER, S.G., ROTH, J.A., NEMUNAITIS, J., LAWRENCE, D.D., KEMP, B.L., CARRASCO, C.H., CONNORS, D.G., EL-NAGGAR, A.K., FOSSELLA, F., GLISSON, B.S., HONG, W.K., KHURI, F.R., KURIE, J.M., LEE, J.J., LEE, J.S., MACK, M., MERRITT, J.A., NGUYEN, D.M., NESBITT, J.C., PEREZ-SOLER, R., PISTERS, K.M., PUTNAM, J.B., JR., RICHLI, W.R., SAVIN, M., SCHRUMP, D.S., SHIN, D.M., SHULKIN, A., WALSH, G.L., WAIT, J., WEILL, D., and WAUGH, M.K. (1999). Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. *J Natl Cancer Inst* **91**, 763-771.

T

- TADA, M., OMATA, M., and OHTO, M. (1991). Clinical application of ras gene mutation for diagnosis of pancreatic adenocarcinoma. *Gastroenterology* **100**, 233-238.
- TAKAYAMA, K., REYNOLDS, P.N., SHORT, J.J., KAWAKAMI, Y., ADACHI, Y., GLASGOW, J.N., ROTS, M.G., KRASNYKH, V., DOUGLAS, J.T., and CUIEL, D.T. (2003). A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. *Virology* **309**, 282-293.
- TAKI, M., KAGAWA, S., NISHIZAKI, M., MIZUGUCHI, H., HAYAKAWA, T., KYO, S., NAGAI, K., URATA, Y., TANAKA, N., and FUJIWARA, T. (2005). Enhanced oncolysis by a tropism-modified telomerase-specific replication-selective adenoviral agent OBP-405 ('Telomelysin-RGD'). *Oncogene* **24**, 3130-3140.
- TATE, A.W., LUNG, T., RADHAKRISHNAN, A., LIM, S.D., LIN, X., and EDLUND, M. (2006). Changes in gap junctional connexin isoforms during prostate cancer progression. *Prostate* **66**, 19-31.
- TATTERSALL, M.H., SLOWIACZEK, P., and DE FAZIO, A. (1983). Regional variation in human extracellular purine levels. *J Lab Clin Med* **102**, 411-420.
- TAUBER, B., and DOBNER, T. (2001). Molecular regulation and biological function of adenovirus early genes: the E4 ORFs. *Gene* **278**, 1-23.
- THOMPSON, D., and EASTON, D.F. (2002). Cancer Incidence in BRCA1 mutation carriers. *J Natl Cancer Inst* **94**, 1358-1365.
- TOMASZEWSKA, R., OKON, K., NOWAK, K., and STACHURA, J. (1998). HER-2/Neu expression as a progression marker in pancreatic intraepithelial neoplasia. *Pol J Pathol* **49**, 83-92.
- TOMKO, R.P., XU, R., and PHILIPSON, L. (1997). HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. *Proc Natl Acad Sci U S A* **94**, 3352-3356.
- TOURAIN, R.L., VAHANIAN, N., RAMSEY, W.J., and BLAESE, R.M. (1998). Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy *in vivo* by pharmacologic manipulation of gap junctions. *Hum Gene Ther* **9**, 2385-2391.
- TOWBIN, H., STAHELIN, T., and GORDON, J. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. *Proc Natl Acad Sci U S A* **76**, 4350-4354.
- TRASK, T.W., TRASK, R.P., AGUILAR-CORDOVA, E., SHINE, H.D., WYDE, P.R., GOODMAN, J.C., HAMILTON, W.J., ROJAS-MARTINEZ, A., CHEN, S.H., WOO, S.L., and GROSSMAN, R.G. (2000). Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. *Mol Ther* **1**, 195-203.
- TSE, C.M., BELT, J.A., JARVIS, S.M., PATERSON, A.R., WU, J.S., and YOUNG, J.D. (1985). Reconstitution studies of the human erythrocyte nucleoside transporter. *J Biol Chem* **260**, 3506-3511.
- TSENG, W.C., DERSE, D., CHENG, Y.C., BROCKMAN, R.W., and BENNETT, L.L., JR. (1982). *In vitro* biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. *Mol Pharmacol* **21**, 474-477.
- TUVESON, D.A., and HINGORANI, S.R. (2005). Ductal pancreatic cancer in humans and mice. *Cold Spring Harb Symp Quant Biol* **70**, 65-72.

TYAGI, M., RUSNATI, M., PRESTA, M., and GIACCA, M. (2001). Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. *J Biol Chem* **276**, 3254-3261.

V

- VALDES, R., ORTEGA, M.A., CASADO, F.J., FELIPE, A., GIL, A., SANCHEZ-POZO, A., and PASTOR-ANGLADA, M. (2000). Nutritional regulation of nucleoside transporter expression in rat small intestine. *Gastroenterology* **119**, 1623-1630.
- VAN BEUSECHEM, V.W., VAN DEN DOEL, P.B., and GERRITSEN, W.R. (2005). Conditionally replicative adenovirus expressing degradation-resistant p53 for enhanced oncolysis of human cancer cells overexpressing murine double minute 2. *Mol Cancer Ther* **4**, 1013-1018.
- VAN BEUSECHEM, V.W., VAN DEN DOEL, P.B., GRILL, J., PINEDO, H.M., and GERRITSEN, W.R. (2002). Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. *Cancer Res* **62**, 6165-6171.
- VAN CUTSEM, E., AERTS, R., HAUSERMANS, K., TOPAL, B., VAN STEENBERGEN, W., and VERSLYPE, C. (2004). Systemic treatment of pancreatic cancer. *Eur J Gastroenterol Hepatol* **16**, 265-274.
- VASEY, P.A., SHULMAN, L.N., CAMPOS, S., DAVIS, J., GORE, M., JOHNSTON, S., KIRN, D.H., O'NEILL, V., SIDDIQUI, N., SEIDEN, M.V., and KAYE, S.B. (2002). Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. *J Clin Oncol* **20**, 1562-1569.
- VIGNE, E., MAHFOUZ, I., DEDIEU, J.F., BRIE, A., PERRICAUDET, M., and YEH, P. (1999). RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. *J Virol* **73**, 5156-5161.
- VILLANUEVA, A., GARCIA, C., PAULES, A.B., VICENTE, M., MEGIAS, M., REYES, G., DE VILLALONGA, P., AGELL, N., LLUIS, F., BACHS, O., and CAPELLA, G. (1998). Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. *Oncogene* **17**, 1969-1978.
- VINCENT, T., PETERSSON, R.F., CRYSTAL, R.G., and LEOPOLD, P.L. (2004). Cytokine-mediated downregulation of coxsackievirus-adenovirus receptor in endothelial cells. *J Virol* **78**, 8047-8058.
- VINDELOV, L., and CHRISTENSEN, I.J. (1990). An integrated set of methods for routine flow cytometric DNA analysis. *Methods Cell Biol* **33**, 127-137.
- VINIK, A., RAFAELOFF, R., PITTENGER, G., ROSENBERG, L., and DUGUID, W. (1997). Induction of pancreatic islet neogenesis. *Horm Metab Res* **29**, 278-293.

W

- WADIA, J.S., STAN, R.V., and DOWDY, S.F. (2004). Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. *Nat Med* **10**, 310-315.
- WALISSER, J.A., and THIES, R.L. (1999). Poly(ADP-ribose) polymerase inhibition in oxidant-stressed endothelial cells prevents oncosis and permits caspase activation and apoptosis. *Exp Cell Res* **251**, 401-413.
- WALLRAPP, C., MULLER-PILLASCH, F., SOLINAS-TOLDO, S., LICHTER, P., FRIESS, H., BUCHLER, M., FINK, T., ADLER, G., and GRESS, T.M. (1997). Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myc as a candidate oncogene. *Cancer Res* **57**, 3135-3139.
- WANG, J., LU, X.X., CHEN, D.Z., LI, S.F., and ZHANG, L.S. (2004). Herpes simplex virus thymidine kinase and ganciclovir suicide gene therapy for human pancreatic cancer. *World J Gastroenterol* **10**, 400-403.
- WANG, J., SCHANER, M.E., THOMASSEN, S., SU, S.F., PIQUETTE-MILLER, M., and GIACOMINI, K.M. (1997). Functional and molecular characteristics of Na(+)-dependent nucleoside transporters. *Pharm Res* **14**, 1524-1532.
- WANG, L., MUNCH-PETERSEN, B., HERRSTROM SJOBERG, A., HELLMAN, U., BERGMAN, T., JORNVALL, H., and ERIKSSON, S. (1999). Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. *FEBS Lett* **443**, 170-174.

- WARSHAW, A.L., and FERNANDEZ-DEL CASTILLO, C. (1992). Pancreatic carcinoma. *N Engl J Med* **326**, 455-465.
- WATTEL, E., PREUDHOMME, C., HECQUET, B., VANRUMBEKE, M., QUESNEL, B., DERVITE, I., MOREL, P., and FENAUX, P. (1994). p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. *Blood* **84**, 3148-3157.
- WHITCOMB, D.C., GORRY, M.C., PRESTON, R.A., FUREY, W., SOSSENHEIMER, M.J., ULRICH, C.D., MARTIN, S.P., GATES, L.K., JR., AMANN, S.T., TOSKES, P.P., LIDDLE, R., MCGRATH, K., UOMO, G., POST, J.C., and EHRlich, G.D. (1996). Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. *Nat Genet* **14**, 141-145.
- WICKHAM, T.J., LEE, G.M., TITUS, J.A., SCINOCCHIA, G., BAKACS, T., KOVESDI, I., and SEGAL, D.M. (1997). Targeted adenovirus-mediated gene delivery to T cells via CD3. *J Virol* **71**, 7663-7669.
- WICKHAM, T.J., MATHIAS, P., CHERESH, D.A., and NEMEROW, G.R. (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. *Cell* **73**, 309-319.
- WILENTZ, R.E., ALBORES-SAAVEDRA, J., and HRUBAN, R.H. (2000a). Mucinous cystic neoplasms of the pancreas. *Semin Diagn Pathol* **17**, 31-42.
- WILENTZ, R.E., GERADTS, J., MAYNARD, R., OFFERHAUS, G.J., KANG, M., GOGGINS, M., YEO, C.J., KERN, S.E., and HRUBAN, R.H. (1998). Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. *Cancer Res* **58**, 4740-4744.
- WILENTZ, R.E., IACOBUIZIO-DONAHUE, C.A., ARGANI, P., MCCARTHY, D.M., PARSONS, J.L., YEO, C.J., KERN, S.E., and HRUBAN, R.H. (2000b). Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. *Cancer Res* **60**, 2002-2006.
- WILENTZ, R.E., SU, G.H., DAI, J.L., SPARKS, A.B., ARGANI, P., SOHN, T.A., YEO, C.J., KERN, S.E., and HRUBAN, R.H. (2000c). Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas : a new marker of DPC4 inactivation. *Am J Pathol* **156**, 37-43.
- WILEY, J.S., JONES, S.P., SAWYER, W.H., and PATERSON, A.R. (1982). Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. *J Clin Invest* **69**, 479-489.
- WILLECKE, K., EIBERGER, J., DEGEN, J., ECKARDT, D., ROMUALDI, A., GULDENAGEL, M., DEUTSCH, U., and SOHL, G. (2002). Structural and functional diversity of connexin genes in the mouse and human genome. *Biol Chem* **383**, 725-737.
- WOHLHUETER, R.M., MCIVOR, R.S., and PLAGEMANN, P.G. (1980). Facilitated transport of uracil and 5-fluorouracil, and permeation of orotic acid into cultured mammalian cells. *J Cell Physiol* **104**, 309-319.
- WRIGHT, A.M., PATERSON, A.R., SOWA, B., AKABUTU, J.J., GRUNDY, P.E., and GATI, W.P. (2002). Cytotoxicity of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from paediatric patients: significance of cellular nucleoside transporter content. *Br J Haematol* **116**, 528-537.

X

- XIA, H., MAO, Q., and DAVIDSON, B.L. (2001). The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. *Nat Biotechnol* **19**, 640-644.
- XUE, L., ZHOU, B., LIU, X., QIU, W., JIN, Z., and YEN, Y. (2003). Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits. *Cancer Res* **63**, 980-986.

Y

- YAMANAKA, Y., FRIESS, H., KOBRIN, M.S., BUCHLER, M., BEGER, H.G., and KORC, M. (1993). Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. *Anticancer Res* **13**, 565-569.
- YAMANO, M., FUJII, H., TAKAGAKI, T., KADOWAKI, N., WATANABE, H., and SHIRAI, T. (2000). Genetic progression and divergence in pancreatic carcinoma. *Am J Pathol* **156**, 2123-2133.

- YAMASAKI, H., and NAUS, C.C. (1996). Role of connexin genes in growth control. *Carcinogenesis* **17**, 1199-1213.
- YANG, D.C., ELLIOTT, R.L., and HEAD, J.F. (2002). Gene targets of antisense therapies in breast cancer. *Expert Opin Ther Targets* **6**, 375-385.
- YAO, S.Y., NG, A.M., VICKERS, M.F., SUNDARAM, M., CASS, C.E., BALDWIN, S.A., and YOUNG, J.D. (2002). Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5-6 region in nucleobase translocation. *J Biol Chem* **277**, 24938-24948.

Z

- ZAJA, F., DI LORETO, C., AMOROSO, V., SALMASO, F., RUSSO, D., SILVESTRI, F., FANIN, R., DAMIANI, D., INFANTI, L., MARIUZZI, L., BELTRAMI, C.A., and BACCARANI, M. (1998). BCL-2 immunohistochemical evaluation in B-cell chronic lymphocytic leukemia and hairy cell leukemia before treatment with fludarabine and 2-chloro-deoxy-adenosine. *Leuk Lymphoma* **28**, 567-572.
- ZEIMET, A.G., and MARTH, C. (2003). Why did p53 gene therapy fail in ovarian cancer? *Lancet Oncol* **4**, 415-422.
- ZHANG, W., and IMPERIALE, M.J. (2003). Requirement of the adenovirus IVa2 protein for virus assembly. *J Virol* **77**, 3586-3594.
- ZHANG, W.W., FANG, X., MAZUR, W., FRENCH, B.A., GEORGES, R.N., and ROTH, J.A. (1994). High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. *Cancer Gene Ther* **1**, 5-13.
- ZHOU, Z., YAMAMOTO, Y., SUGAI, F., YOSHIDA, K., KISHIMA, Y., SUMI, H., NAKAMURA, H., and SAKODA, S. (2004). Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus. *J Biol Chem* **279**, 27320-27326.
- ZONG, W.X., DITSWORTH, D., BAUER, D.E., WANG, Z.Q., and THOMPSON, C.B. (2004). Alkylating DNA damage stimulates a regulated form of necrotic cell death. *Genes Dev* **18**, 1272-1282.



www.phdcomics.com

DESK ENTROPY


JORGE CHAM © 2005

Definition

Desk entropy is a spatiodynamic quantity that measures a workspace's degree of disorder, and the inability to find anything when you really need it.

Any spontaneous activity, whether productive or unproductive, disperses crap matter and increases overall desk entropy.

Efforts to reverse desk entropy are temporary, and inevitably decrease over time.



Units: Junk-height/Area

www.phdcomics.com

A tots els que hagi pogut molestar el meu caos organitzat.
 Ho sento però no ho he pogut evitar, com podeu veure és llei de vida.